User login
Take-home test strips allow drug users to detect fentanyl
Illicit drug users seem to overwhelmingly appreciate being able to use take-home test strips to detect the extremely common presence of dangerous fentanyl in opioids and other drugs, a new study finds. More than 95% said they’d use the inexpensive strips again.
said study lead author addiction medicine specialist Sukhpreet Klaire, MD, of the British Columbia Center on Substance Use in Vancouver, in an interview.
Dr. Klaire presented the study findings at the virtual annual meeting of the College on Problems of Drug Dependence.
Researchers in Vancouver distributed take-home fentanyl test strip kits at 10 sites that allow users to test their illicit drugs. The 218 participants performed 1,680 tests, mainly (73%) for opioids, over 3 months in 2019. Of the participants, 61% were male, and the average age was 36 (interquartile range, 29-47). About 30% described themselves as indigenous Canadians (First Nations).
About 90% of the opioid samples tested at home were positive for fentanyl, about the same level as samples tested at clinics. Fentanyl is very potent and linked to the huge rise in overdose deaths in the United States.
Fentanyl test strips aren’t new. According to the Harm Reduction Coalition, they originally were developed to detect fentanyl in urine samples but were jury-rigged in Vancouver to work on samples of illicit drugs. “We literally just repurposed it,” Dr. Klaire said. “It’s the same strip.”
Users test their drugs by dissolving a small sample in water. Then then dip the test strip, which provides readings similar to those in a pregnancy test. If a sample turns up positive for fentanyl, Dr. Klaire said, users may discard the drug or “be more careful with it.”
When asked what they would do if a sample turned up positive, 27% said they’d make a “positive change,” such as using less or using more slowly (n = 45) or making sure that someone else is present in case of an overdose (n = 26). But most, 71%, reported no change in behavior.
Previously, researchers in Rhode Island and North Carolina also found that some users adopted safer behaviors – such as throwing out their drugs or using less often – after testing their drugs with the strips.
The strips cost about 75 cents, Dr. Klaire said.
Harm-reduction strategies are controversial, and fentanyl test strips aren’t any exemption. “The entire approach is based on the premise that a drug user poised to use a drug is making rational choices, is weighing pros and cons, and is thinking completely logically about his or her drug use. Based on my clinical experience, I know this could not be further from the truth,” wrote Elinore F. McCance-Katz, MD, PhD, assistant secretary for Mental Health and Substance Use with the Department of Health & Human Services, in a 2018 blog post.
But Dr. Klaire said the patients in the new study are highly dependent on opioids. “The drug supply is heavily contaminated [with fentanyl],” he said, “but even when people know it’s contaminated, they still need to go ahead and use it.”
In an interview, epidemiologist Brandon Marshall, PhD, of Brown University, Providence, R.I., who has conducted fentanyl test strip research, called the study results “compelling.”
“The researchers found that the fentanyl test strips had a very high level of acceptability – over 95% said they would use the strips again – which is remarkably similar to what we found in our work here in Rhode Island,” he said. “Taken together, these studies show that take-home test strips are a feasible, acceptable, and effective strategy for people who use drugs to reduce their risk of fentanyl overdose.”
He added that “fentanyl test strips help people make more informed decisions about their drug use and reducing their risk of overdose.”
However, he said, “one of important limitations of the strips is that they do not detect all contaminants that put persons at risk of overdose. Just because a test result is negative does not mean that the drug is 100% safe.”
Kimberly Sue, MD, PhD, medical director of the National Harm Reduction Coalition, said in an interview that the research is “important,” but noted that many drug users already have been using fentanyl test strips on their own. “We should be focusing on investing in variety of other interventions that could keep more people safe against nonfatal and fatal opioid overdoses, including structural interventions such as safe supply, housing and community with appropriate supports, low barrier access to medication for opioid use disorder, and safe consumption spaces,” she said.
No study funding was reported. Dr. Klaire disclosed participating in a research fellowship and a research in addiction medical scholars program, both funded by the National Institute of Drug Abuse. Dr. Sue reported no relevant disclosures. Dr. Marshall reported that he has collaborated frequently with one of the coauthors of the Vancouver study.
Illicit drug users seem to overwhelmingly appreciate being able to use take-home test strips to detect the extremely common presence of dangerous fentanyl in opioids and other drugs, a new study finds. More than 95% said they’d use the inexpensive strips again.
said study lead author addiction medicine specialist Sukhpreet Klaire, MD, of the British Columbia Center on Substance Use in Vancouver, in an interview.
Dr. Klaire presented the study findings at the virtual annual meeting of the College on Problems of Drug Dependence.
Researchers in Vancouver distributed take-home fentanyl test strip kits at 10 sites that allow users to test their illicit drugs. The 218 participants performed 1,680 tests, mainly (73%) for opioids, over 3 months in 2019. Of the participants, 61% were male, and the average age was 36 (interquartile range, 29-47). About 30% described themselves as indigenous Canadians (First Nations).
About 90% of the opioid samples tested at home were positive for fentanyl, about the same level as samples tested at clinics. Fentanyl is very potent and linked to the huge rise in overdose deaths in the United States.
Fentanyl test strips aren’t new. According to the Harm Reduction Coalition, they originally were developed to detect fentanyl in urine samples but were jury-rigged in Vancouver to work on samples of illicit drugs. “We literally just repurposed it,” Dr. Klaire said. “It’s the same strip.”
Users test their drugs by dissolving a small sample in water. Then then dip the test strip, which provides readings similar to those in a pregnancy test. If a sample turns up positive for fentanyl, Dr. Klaire said, users may discard the drug or “be more careful with it.”
When asked what they would do if a sample turned up positive, 27% said they’d make a “positive change,” such as using less or using more slowly (n = 45) or making sure that someone else is present in case of an overdose (n = 26). But most, 71%, reported no change in behavior.
Previously, researchers in Rhode Island and North Carolina also found that some users adopted safer behaviors – such as throwing out their drugs or using less often – after testing their drugs with the strips.
The strips cost about 75 cents, Dr. Klaire said.
Harm-reduction strategies are controversial, and fentanyl test strips aren’t any exemption. “The entire approach is based on the premise that a drug user poised to use a drug is making rational choices, is weighing pros and cons, and is thinking completely logically about his or her drug use. Based on my clinical experience, I know this could not be further from the truth,” wrote Elinore F. McCance-Katz, MD, PhD, assistant secretary for Mental Health and Substance Use with the Department of Health & Human Services, in a 2018 blog post.
But Dr. Klaire said the patients in the new study are highly dependent on opioids. “The drug supply is heavily contaminated [with fentanyl],” he said, “but even when people know it’s contaminated, they still need to go ahead and use it.”
In an interview, epidemiologist Brandon Marshall, PhD, of Brown University, Providence, R.I., who has conducted fentanyl test strip research, called the study results “compelling.”
“The researchers found that the fentanyl test strips had a very high level of acceptability – over 95% said they would use the strips again – which is remarkably similar to what we found in our work here in Rhode Island,” he said. “Taken together, these studies show that take-home test strips are a feasible, acceptable, and effective strategy for people who use drugs to reduce their risk of fentanyl overdose.”
He added that “fentanyl test strips help people make more informed decisions about their drug use and reducing their risk of overdose.”
However, he said, “one of important limitations of the strips is that they do not detect all contaminants that put persons at risk of overdose. Just because a test result is negative does not mean that the drug is 100% safe.”
Kimberly Sue, MD, PhD, medical director of the National Harm Reduction Coalition, said in an interview that the research is “important,” but noted that many drug users already have been using fentanyl test strips on their own. “We should be focusing on investing in variety of other interventions that could keep more people safe against nonfatal and fatal opioid overdoses, including structural interventions such as safe supply, housing and community with appropriate supports, low barrier access to medication for opioid use disorder, and safe consumption spaces,” she said.
No study funding was reported. Dr. Klaire disclosed participating in a research fellowship and a research in addiction medical scholars program, both funded by the National Institute of Drug Abuse. Dr. Sue reported no relevant disclosures. Dr. Marshall reported that he has collaborated frequently with one of the coauthors of the Vancouver study.
Illicit drug users seem to overwhelmingly appreciate being able to use take-home test strips to detect the extremely common presence of dangerous fentanyl in opioids and other drugs, a new study finds. More than 95% said they’d use the inexpensive strips again.
said study lead author addiction medicine specialist Sukhpreet Klaire, MD, of the British Columbia Center on Substance Use in Vancouver, in an interview.
Dr. Klaire presented the study findings at the virtual annual meeting of the College on Problems of Drug Dependence.
Researchers in Vancouver distributed take-home fentanyl test strip kits at 10 sites that allow users to test their illicit drugs. The 218 participants performed 1,680 tests, mainly (73%) for opioids, over 3 months in 2019. Of the participants, 61% were male, and the average age was 36 (interquartile range, 29-47). About 30% described themselves as indigenous Canadians (First Nations).
About 90% of the opioid samples tested at home were positive for fentanyl, about the same level as samples tested at clinics. Fentanyl is very potent and linked to the huge rise in overdose deaths in the United States.
Fentanyl test strips aren’t new. According to the Harm Reduction Coalition, they originally were developed to detect fentanyl in urine samples but were jury-rigged in Vancouver to work on samples of illicit drugs. “We literally just repurposed it,” Dr. Klaire said. “It’s the same strip.”
Users test their drugs by dissolving a small sample in water. Then then dip the test strip, which provides readings similar to those in a pregnancy test. If a sample turns up positive for fentanyl, Dr. Klaire said, users may discard the drug or “be more careful with it.”
When asked what they would do if a sample turned up positive, 27% said they’d make a “positive change,” such as using less or using more slowly (n = 45) or making sure that someone else is present in case of an overdose (n = 26). But most, 71%, reported no change in behavior.
Previously, researchers in Rhode Island and North Carolina also found that some users adopted safer behaviors – such as throwing out their drugs or using less often – after testing their drugs with the strips.
The strips cost about 75 cents, Dr. Klaire said.
Harm-reduction strategies are controversial, and fentanyl test strips aren’t any exemption. “The entire approach is based on the premise that a drug user poised to use a drug is making rational choices, is weighing pros and cons, and is thinking completely logically about his or her drug use. Based on my clinical experience, I know this could not be further from the truth,” wrote Elinore F. McCance-Katz, MD, PhD, assistant secretary for Mental Health and Substance Use with the Department of Health & Human Services, in a 2018 blog post.
But Dr. Klaire said the patients in the new study are highly dependent on opioids. “The drug supply is heavily contaminated [with fentanyl],” he said, “but even when people know it’s contaminated, they still need to go ahead and use it.”
In an interview, epidemiologist Brandon Marshall, PhD, of Brown University, Providence, R.I., who has conducted fentanyl test strip research, called the study results “compelling.”
“The researchers found that the fentanyl test strips had a very high level of acceptability – over 95% said they would use the strips again – which is remarkably similar to what we found in our work here in Rhode Island,” he said. “Taken together, these studies show that take-home test strips are a feasible, acceptable, and effective strategy for people who use drugs to reduce their risk of fentanyl overdose.”
He added that “fentanyl test strips help people make more informed decisions about their drug use and reducing their risk of overdose.”
However, he said, “one of important limitations of the strips is that they do not detect all contaminants that put persons at risk of overdose. Just because a test result is negative does not mean that the drug is 100% safe.”
Kimberly Sue, MD, PhD, medical director of the National Harm Reduction Coalition, said in an interview that the research is “important,” but noted that many drug users already have been using fentanyl test strips on their own. “We should be focusing on investing in variety of other interventions that could keep more people safe against nonfatal and fatal opioid overdoses, including structural interventions such as safe supply, housing and community with appropriate supports, low barrier access to medication for opioid use disorder, and safe consumption spaces,” she said.
No study funding was reported. Dr. Klaire disclosed participating in a research fellowship and a research in addiction medical scholars program, both funded by the National Institute of Drug Abuse. Dr. Sue reported no relevant disclosures. Dr. Marshall reported that he has collaborated frequently with one of the coauthors of the Vancouver study.
FROM CPDD 2020
Topline results for novel intranasal med to treat opioid overdose
Topline results show positive results for the experimental intranasal nalmefene product OX125 for opioid overdose reversal, Orexo, the drug’s manufacturer, announced on June 30.
A crossover, comparative bioavailability study was conducted in healthy volunteers to assess nalmefene absorption of three development formulations of OX125. Preliminary results showed “extensive and rapid absorption” across all three formulations versus an intramuscular injection of nalmefene, Orexo reported.
“As the U.S. heroin crisis has developed to a fentanyl crisis, the medical need for novel and more powerful opioid rescue medications is vast,” Nikolaj Sørensen, president and CEO of Orexo, said in a press release.
“The need has also escalated due to the COVID-19 pandemic as the consequences of social distancing and economic weakness are expected to lead to a significant increase in mental health issues and substance use disorders,” Mr. Sørensen added.
Robert Rönn, vice president and head of research and development at Orexo, noted in the same release that the company will now be working with the Food and Drug Administration “to identify the optimal route to market.”
There were more than 31,000 fatalities from highly potent synthetic opioids in the United States in 2018, the manufacturer reported. “Like naloxone, nalmefene is an opioid antagonist that acts by blocking the effects of opioids at the opioid receptors.”
However, nalmefene has a longer half-life than naloxone. These longer-acting properties may be “of particular value to protect against renarcotization (second overdose), as the antagonist wears off,” according to an Orexo press release.
In addition to showing rapid absorption across all formulations studied, study results showed “good tolerability, supporting the viability” of the treatment as an opioid overdose rescue medication, the company said.
“This is not only a proof of concept for our wholly owned OX125 product, but also a demonstration of the value of our novel nasal technology platform,” Mr. Rönn said.
“Alongside OX124, our naloxone rescue project, OX125 will be an important lifesaving addition in our commitment to helping patients suffering from opioid addiction in all phases,” Mr. Sørensen added.
A version of this article originally appeared on Medscape.com.
Topline results show positive results for the experimental intranasal nalmefene product OX125 for opioid overdose reversal, Orexo, the drug’s manufacturer, announced on June 30.
A crossover, comparative bioavailability study was conducted in healthy volunteers to assess nalmefene absorption of three development formulations of OX125. Preliminary results showed “extensive and rapid absorption” across all three formulations versus an intramuscular injection of nalmefene, Orexo reported.
“As the U.S. heroin crisis has developed to a fentanyl crisis, the medical need for novel and more powerful opioid rescue medications is vast,” Nikolaj Sørensen, president and CEO of Orexo, said in a press release.
“The need has also escalated due to the COVID-19 pandemic as the consequences of social distancing and economic weakness are expected to lead to a significant increase in mental health issues and substance use disorders,” Mr. Sørensen added.
Robert Rönn, vice president and head of research and development at Orexo, noted in the same release that the company will now be working with the Food and Drug Administration “to identify the optimal route to market.”
There were more than 31,000 fatalities from highly potent synthetic opioids in the United States in 2018, the manufacturer reported. “Like naloxone, nalmefene is an opioid antagonist that acts by blocking the effects of opioids at the opioid receptors.”
However, nalmefene has a longer half-life than naloxone. These longer-acting properties may be “of particular value to protect against renarcotization (second overdose), as the antagonist wears off,” according to an Orexo press release.
In addition to showing rapid absorption across all formulations studied, study results showed “good tolerability, supporting the viability” of the treatment as an opioid overdose rescue medication, the company said.
“This is not only a proof of concept for our wholly owned OX125 product, but also a demonstration of the value of our novel nasal technology platform,” Mr. Rönn said.
“Alongside OX124, our naloxone rescue project, OX125 will be an important lifesaving addition in our commitment to helping patients suffering from opioid addiction in all phases,” Mr. Sørensen added.
A version of this article originally appeared on Medscape.com.
Topline results show positive results for the experimental intranasal nalmefene product OX125 for opioid overdose reversal, Orexo, the drug’s manufacturer, announced on June 30.
A crossover, comparative bioavailability study was conducted in healthy volunteers to assess nalmefene absorption of three development formulations of OX125. Preliminary results showed “extensive and rapid absorption” across all three formulations versus an intramuscular injection of nalmefene, Orexo reported.
“As the U.S. heroin crisis has developed to a fentanyl crisis, the medical need for novel and more powerful opioid rescue medications is vast,” Nikolaj Sørensen, president and CEO of Orexo, said in a press release.
“The need has also escalated due to the COVID-19 pandemic as the consequences of social distancing and economic weakness are expected to lead to a significant increase in mental health issues and substance use disorders,” Mr. Sørensen added.
Robert Rönn, vice president and head of research and development at Orexo, noted in the same release that the company will now be working with the Food and Drug Administration “to identify the optimal route to market.”
There were more than 31,000 fatalities from highly potent synthetic opioids in the United States in 2018, the manufacturer reported. “Like naloxone, nalmefene is an opioid antagonist that acts by blocking the effects of opioids at the opioid receptors.”
However, nalmefene has a longer half-life than naloxone. These longer-acting properties may be “of particular value to protect against renarcotization (second overdose), as the antagonist wears off,” according to an Orexo press release.
In addition to showing rapid absorption across all formulations studied, study results showed “good tolerability, supporting the viability” of the treatment as an opioid overdose rescue medication, the company said.
“This is not only a proof of concept for our wholly owned OX125 product, but also a demonstration of the value of our novel nasal technology platform,” Mr. Rönn said.
“Alongside OX124, our naloxone rescue project, OX125 will be an important lifesaving addition in our commitment to helping patients suffering from opioid addiction in all phases,” Mr. Sørensen added.
A version of this article originally appeared on Medscape.com.
Rethinking the language of substance abuse
In December 2019, Seattle Seahawks wide receiver Josh Gordon was suspended indefinitely from the NFL for violation of the league’s substance abuse policy. Gordon, once known as one of the most promising wide receivers of the last few decades, had a tumultuous relationship with the NFL as a result of his struggles with substance use. However, the headlines from major sports and news outlets often describe Gordon and other professional and collegiate athletes who struggle with substance use as “violating policies of abuse.” Media coverage of such athletes frequently imposes labels such as “violation” and “abuse,” implying a greater level of personal responsibility and willful misconduct than the biological process of addiction would typically allow. Gordon’s story brought attention not only to the adversity and impairments of substance use, but also the stigmatizing language that often accompanies it.
Shifting to less stigmatizing terminology
In DMS-5, use of the terminology substance use disorder fosters a more biologically-based model of behavior, and encourages recovery-oriented terminology.1 However, for most collegiate and professional sports leagues, the policies regarding substance use often use the term substance abuse, which can perpetuate stigma and a misunderstanding of the underpinnings of substance use, insinuating a sense of personal responsibility, deliberate misconduct, and criminality. When an individual is referred to as an “abuser” of substances, this might suggest that they are willful perpetrators of the disease on themselves, and thus may be undeserving of care.2 Individuals referred to as “substance abusers” rather than having a substance use disorder are more likely to be subjected to negative perceptions and evaluations of their behaviors, particularly by clinicians.
Individuals with substance use disorders are often viewed more negatively than individuals with physical or other psychiatric disorders, and are among the most stigmatized and marginalized groups in health care.4,5 Today, lawmakers, advocates, and health care professionals across the country are working to integrate destigmatizing language into media, policy, and educational settings in order to characterize substance use as a neurobiological process rather than a moral fault.6 For example, legislation in Maine passed in 2018 removed references to stigmatizing terms in policies related to substance use, replacing substance abuse and drug addict with recovery-oriented terminology such as substance use disorder and person with a substance use disorder.7
Individuals with substance use disorders often fear judgment and stigma during clinical encounters, and commonly cite this as a reason to avoid seeking care.8 Words matter, and if we are not careful, the language we use can convey meaning and attitudes that perpetuate the stigma that prevents so many from accessing treatment.9,10 Individuals with a substance use disorder should feel institutionally supported, and the language of policies and the clinicians who treat these patients should reflect this as well.
1. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Wakeman SE. Language and addiction: choosing words wisely. Am J Public Health. 2013;103(4):e1‐e2.
3. Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21(3):202‐207.
4. Corrigan PW, Kuwabara SA, O’Shaughnessy J. The public stigma of mental illness and drug addiction: findings from a stratified random sample. Journal of Social Work. 2009;9(2):139-147.
5. Barry CL, McGinty EE, Pescosolido BA, et al. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65(10):1269‐1272.
6. Office of National Drug Control Policy. Changing the language of addiction. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Memo%20-%20Changing%20Federal%20Terminology%20Regrading%20Substance%20Use%20and%20Substance%20Use%20Disorders.pdf. Published January 9, 2017. Accessed June 8, 2020.
7. Flaherty N. Why language matters when describing substance use disorder in Maine. http://www.mainepublic.org/post/why-language-matters-when-describing-substance-use-disorder-maine. Published May 16, 2018. Accessed June 8, 2020.
8. Merrill JO, Rhodes LA, Deyo RA, et al. Mutual mistrust in the medical care of drug users: the keys to the “narc” cabinet. J Gen Intern Med. 2002;17(5):327‐333.
9. Yang LH, Wong LY, Grivel MM, et al. Stigma and substance use disorders: an international phenomenon. Curr Opin Psychiatry. 2017;30(5):378‐388.
10. Broyles LM, Binswanger IA, Jenkins JA, et al. Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Subst Abus. 2014;35(3):217‐221.
In December 2019, Seattle Seahawks wide receiver Josh Gordon was suspended indefinitely from the NFL for violation of the league’s substance abuse policy. Gordon, once known as one of the most promising wide receivers of the last few decades, had a tumultuous relationship with the NFL as a result of his struggles with substance use. However, the headlines from major sports and news outlets often describe Gordon and other professional and collegiate athletes who struggle with substance use as “violating policies of abuse.” Media coverage of such athletes frequently imposes labels such as “violation” and “abuse,” implying a greater level of personal responsibility and willful misconduct than the biological process of addiction would typically allow. Gordon’s story brought attention not only to the adversity and impairments of substance use, but also the stigmatizing language that often accompanies it.
Shifting to less stigmatizing terminology
In DMS-5, use of the terminology substance use disorder fosters a more biologically-based model of behavior, and encourages recovery-oriented terminology.1 However, for most collegiate and professional sports leagues, the policies regarding substance use often use the term substance abuse, which can perpetuate stigma and a misunderstanding of the underpinnings of substance use, insinuating a sense of personal responsibility, deliberate misconduct, and criminality. When an individual is referred to as an “abuser” of substances, this might suggest that they are willful perpetrators of the disease on themselves, and thus may be undeserving of care.2 Individuals referred to as “substance abusers” rather than having a substance use disorder are more likely to be subjected to negative perceptions and evaluations of their behaviors, particularly by clinicians.
Individuals with substance use disorders are often viewed more negatively than individuals with physical or other psychiatric disorders, and are among the most stigmatized and marginalized groups in health care.4,5 Today, lawmakers, advocates, and health care professionals across the country are working to integrate destigmatizing language into media, policy, and educational settings in order to characterize substance use as a neurobiological process rather than a moral fault.6 For example, legislation in Maine passed in 2018 removed references to stigmatizing terms in policies related to substance use, replacing substance abuse and drug addict with recovery-oriented terminology such as substance use disorder and person with a substance use disorder.7
Individuals with substance use disorders often fear judgment and stigma during clinical encounters, and commonly cite this as a reason to avoid seeking care.8 Words matter, and if we are not careful, the language we use can convey meaning and attitudes that perpetuate the stigma that prevents so many from accessing treatment.9,10 Individuals with a substance use disorder should feel institutionally supported, and the language of policies and the clinicians who treat these patients should reflect this as well.
In December 2019, Seattle Seahawks wide receiver Josh Gordon was suspended indefinitely from the NFL for violation of the league’s substance abuse policy. Gordon, once known as one of the most promising wide receivers of the last few decades, had a tumultuous relationship with the NFL as a result of his struggles with substance use. However, the headlines from major sports and news outlets often describe Gordon and other professional and collegiate athletes who struggle with substance use as “violating policies of abuse.” Media coverage of such athletes frequently imposes labels such as “violation” and “abuse,” implying a greater level of personal responsibility and willful misconduct than the biological process of addiction would typically allow. Gordon’s story brought attention not only to the adversity and impairments of substance use, but also the stigmatizing language that often accompanies it.
Shifting to less stigmatizing terminology
In DMS-5, use of the terminology substance use disorder fosters a more biologically-based model of behavior, and encourages recovery-oriented terminology.1 However, for most collegiate and professional sports leagues, the policies regarding substance use often use the term substance abuse, which can perpetuate stigma and a misunderstanding of the underpinnings of substance use, insinuating a sense of personal responsibility, deliberate misconduct, and criminality. When an individual is referred to as an “abuser” of substances, this might suggest that they are willful perpetrators of the disease on themselves, and thus may be undeserving of care.2 Individuals referred to as “substance abusers” rather than having a substance use disorder are more likely to be subjected to negative perceptions and evaluations of their behaviors, particularly by clinicians.
Individuals with substance use disorders are often viewed more negatively than individuals with physical or other psychiatric disorders, and are among the most stigmatized and marginalized groups in health care.4,5 Today, lawmakers, advocates, and health care professionals across the country are working to integrate destigmatizing language into media, policy, and educational settings in order to characterize substance use as a neurobiological process rather than a moral fault.6 For example, legislation in Maine passed in 2018 removed references to stigmatizing terms in policies related to substance use, replacing substance abuse and drug addict with recovery-oriented terminology such as substance use disorder and person with a substance use disorder.7
Individuals with substance use disorders often fear judgment and stigma during clinical encounters, and commonly cite this as a reason to avoid seeking care.8 Words matter, and if we are not careful, the language we use can convey meaning and attitudes that perpetuate the stigma that prevents so many from accessing treatment.9,10 Individuals with a substance use disorder should feel institutionally supported, and the language of policies and the clinicians who treat these patients should reflect this as well.
1. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Wakeman SE. Language and addiction: choosing words wisely. Am J Public Health. 2013;103(4):e1‐e2.
3. Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21(3):202‐207.
4. Corrigan PW, Kuwabara SA, O’Shaughnessy J. The public stigma of mental illness and drug addiction: findings from a stratified random sample. Journal of Social Work. 2009;9(2):139-147.
5. Barry CL, McGinty EE, Pescosolido BA, et al. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65(10):1269‐1272.
6. Office of National Drug Control Policy. Changing the language of addiction. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Memo%20-%20Changing%20Federal%20Terminology%20Regrading%20Substance%20Use%20and%20Substance%20Use%20Disorders.pdf. Published January 9, 2017. Accessed June 8, 2020.
7. Flaherty N. Why language matters when describing substance use disorder in Maine. http://www.mainepublic.org/post/why-language-matters-when-describing-substance-use-disorder-maine. Published May 16, 2018. Accessed June 8, 2020.
8. Merrill JO, Rhodes LA, Deyo RA, et al. Mutual mistrust in the medical care of drug users: the keys to the “narc” cabinet. J Gen Intern Med. 2002;17(5):327‐333.
9. Yang LH, Wong LY, Grivel MM, et al. Stigma and substance use disorders: an international phenomenon. Curr Opin Psychiatry. 2017;30(5):378‐388.
10. Broyles LM, Binswanger IA, Jenkins JA, et al. Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Subst Abus. 2014;35(3):217‐221.
1. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Wakeman SE. Language and addiction: choosing words wisely. Am J Public Health. 2013;103(4):e1‐e2.
3. Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21(3):202‐207.
4. Corrigan PW, Kuwabara SA, O’Shaughnessy J. The public stigma of mental illness and drug addiction: findings from a stratified random sample. Journal of Social Work. 2009;9(2):139-147.
5. Barry CL, McGinty EE, Pescosolido BA, et al. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv. 2014;65(10):1269‐1272.
6. Office of National Drug Control Policy. Changing the language of addiction. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Memo%20-%20Changing%20Federal%20Terminology%20Regrading%20Substance%20Use%20and%20Substance%20Use%20Disorders.pdf. Published January 9, 2017. Accessed June 8, 2020.
7. Flaherty N. Why language matters when describing substance use disorder in Maine. http://www.mainepublic.org/post/why-language-matters-when-describing-substance-use-disorder-maine. Published May 16, 2018. Accessed June 8, 2020.
8. Merrill JO, Rhodes LA, Deyo RA, et al. Mutual mistrust in the medical care of drug users: the keys to the “narc” cabinet. J Gen Intern Med. 2002;17(5):327‐333.
9. Yang LH, Wong LY, Grivel MM, et al. Stigma and substance use disorders: an international phenomenon. Curr Opin Psychiatry. 2017;30(5):378‐388.
10. Broyles LM, Binswanger IA, Jenkins JA, et al. Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Subst Abus. 2014;35(3):217‐221.
Report describes intoxication with new psychoactive substance
When evaluated at local emergency departments, lethargy and slurred speech were the most common clinical findings.
One student had mild respiratory depression with a respiratory rate of 10 breaths per minute.
“All patients had sufficient clinical improvement within 6 hours such that they could be discharged from the hospital,” according to a description of the cases that was published online in Pediatrics.
The report is the first to detail clinical toxicity from flualprazolam, and “it is likely that physicians will again encounter patients” with intoxication from this new psychoactive drug, said Adam Blumenberg, MD, of Oregon Health & Science University in Portland and colleagues.
Internet purchasing has increased rates of exposure to new psychoactive substances since the early 2000s, and law enforcement agents have seized tons of these drugs. “In the United States, the incidence of exposures to designer benzodiazepines in particular has been rising since 2014,” the authors said.
According to an addiction researcher, the COVID-19 pandemic may exacerbate abuse of designer benzodiazepines.
“This is an important paper describing what medical examiners, pathologists, and emergency rooms have been seeing recently – an increase in designer benzodiazepines,” commented Mark S. Gold, MD, adjunct professor of psychiatry at Washington University in St. Louis. “Recent increases in these drugs have started to be seen in many locations as the traditional drugs of abuse, grown and distributed in bulk, have been disrupted” by the pandemic, he said in an interview. Although it may be too early for such cases to appear in Centers for Disease Control and Prevention reports, they can be described in studies like this one and, “I suspect, sadly, in medical examiner case reports.”
Flualprazolam, known colloquially as Hulk, is structurally related to the Food and Drug Administration–approved drugs alprazolam and triazolam. During 1 week in June 2019, the patients in Oregon received the drug as a free sample from another student from their Oregon high school. They believed it was commercial Xanax (alprazolam). “The flualprazolam tablets were identical in appearance and labeling to 2-mg tablets of alprazolam,” according to the report. “This indicates an intentionally counterfeit product entering the drug supply chain.”
Five of the six patients were boys, and they ranged in age from 14 to 16 years. The patient with mild respiratory depression received 0.4-mg naloxone, which physicians gave empirically because of the unknown identity of the drug, but did not respond. Two of the six patients initially felt drowsy but were asymptomatic during the clinical evaluation.
A urine immunoassay was performed in five of the patients, and all tested positive for benzodiazepines. One patient also tested positive for cannabinoids. Analysis of a tablet fragment revealed that it contained flualprazolam.
“Although flualprazolam intoxication cannot be clinically differentiated from that of other benzodiazepines without advanced testing, patient management should be the same,” Dr. Blumenberg and coauthors said. “For mild to moderate intoxication, patients should be treated with close monitoring and supportive care until symptom resolution. The benzodiazepine antidote flumazenil may be considered a safe and effective antidote in pediatric patients with significant CNS or respiratory depression. In patients for whom there is a concern of benzodiazepine dependence and flumazenil-induced seizures, airway protection and mechanical ventilation may be considered.”
Although patients rarely die from isolated benzodiazepine toxicity, death from respiratory depression or aspiration is more common when benzodiazepine toxicity occurs “in combination with alcohol, opioids, or other sedatives,” the authors noted. In addition, counterfeit alprazolam tablets have contained adulterants such as fentanyl and the opioid U-47700, which can be deadly.
The authors had no relevant financial disclosures, and there was no external funding for the study.
SOURCE: Blumenberg A et al. Pediatrics. 2020 Jun 24. doi: 10.1542/peds.2019-2953.
When evaluated at local emergency departments, lethargy and slurred speech were the most common clinical findings.
One student had mild respiratory depression with a respiratory rate of 10 breaths per minute.
“All patients had sufficient clinical improvement within 6 hours such that they could be discharged from the hospital,” according to a description of the cases that was published online in Pediatrics.
The report is the first to detail clinical toxicity from flualprazolam, and “it is likely that physicians will again encounter patients” with intoxication from this new psychoactive drug, said Adam Blumenberg, MD, of Oregon Health & Science University in Portland and colleagues.
Internet purchasing has increased rates of exposure to new psychoactive substances since the early 2000s, and law enforcement agents have seized tons of these drugs. “In the United States, the incidence of exposures to designer benzodiazepines in particular has been rising since 2014,” the authors said.
According to an addiction researcher, the COVID-19 pandemic may exacerbate abuse of designer benzodiazepines.
“This is an important paper describing what medical examiners, pathologists, and emergency rooms have been seeing recently – an increase in designer benzodiazepines,” commented Mark S. Gold, MD, adjunct professor of psychiatry at Washington University in St. Louis. “Recent increases in these drugs have started to be seen in many locations as the traditional drugs of abuse, grown and distributed in bulk, have been disrupted” by the pandemic, he said in an interview. Although it may be too early for such cases to appear in Centers for Disease Control and Prevention reports, they can be described in studies like this one and, “I suspect, sadly, in medical examiner case reports.”
Flualprazolam, known colloquially as Hulk, is structurally related to the Food and Drug Administration–approved drugs alprazolam and triazolam. During 1 week in June 2019, the patients in Oregon received the drug as a free sample from another student from their Oregon high school. They believed it was commercial Xanax (alprazolam). “The flualprazolam tablets were identical in appearance and labeling to 2-mg tablets of alprazolam,” according to the report. “This indicates an intentionally counterfeit product entering the drug supply chain.”
Five of the six patients were boys, and they ranged in age from 14 to 16 years. The patient with mild respiratory depression received 0.4-mg naloxone, which physicians gave empirically because of the unknown identity of the drug, but did not respond. Two of the six patients initially felt drowsy but were asymptomatic during the clinical evaluation.
A urine immunoassay was performed in five of the patients, and all tested positive for benzodiazepines. One patient also tested positive for cannabinoids. Analysis of a tablet fragment revealed that it contained flualprazolam.
“Although flualprazolam intoxication cannot be clinically differentiated from that of other benzodiazepines without advanced testing, patient management should be the same,” Dr. Blumenberg and coauthors said. “For mild to moderate intoxication, patients should be treated with close monitoring and supportive care until symptom resolution. The benzodiazepine antidote flumazenil may be considered a safe and effective antidote in pediatric patients with significant CNS or respiratory depression. In patients for whom there is a concern of benzodiazepine dependence and flumazenil-induced seizures, airway protection and mechanical ventilation may be considered.”
Although patients rarely die from isolated benzodiazepine toxicity, death from respiratory depression or aspiration is more common when benzodiazepine toxicity occurs “in combination with alcohol, opioids, or other sedatives,” the authors noted. In addition, counterfeit alprazolam tablets have contained adulterants such as fentanyl and the opioid U-47700, which can be deadly.
The authors had no relevant financial disclosures, and there was no external funding for the study.
SOURCE: Blumenberg A et al. Pediatrics. 2020 Jun 24. doi: 10.1542/peds.2019-2953.
When evaluated at local emergency departments, lethargy and slurred speech were the most common clinical findings.
One student had mild respiratory depression with a respiratory rate of 10 breaths per minute.
“All patients had sufficient clinical improvement within 6 hours such that they could be discharged from the hospital,” according to a description of the cases that was published online in Pediatrics.
The report is the first to detail clinical toxicity from flualprazolam, and “it is likely that physicians will again encounter patients” with intoxication from this new psychoactive drug, said Adam Blumenberg, MD, of Oregon Health & Science University in Portland and colleagues.
Internet purchasing has increased rates of exposure to new psychoactive substances since the early 2000s, and law enforcement agents have seized tons of these drugs. “In the United States, the incidence of exposures to designer benzodiazepines in particular has been rising since 2014,” the authors said.
According to an addiction researcher, the COVID-19 pandemic may exacerbate abuse of designer benzodiazepines.
“This is an important paper describing what medical examiners, pathologists, and emergency rooms have been seeing recently – an increase in designer benzodiazepines,” commented Mark S. Gold, MD, adjunct professor of psychiatry at Washington University in St. Louis. “Recent increases in these drugs have started to be seen in many locations as the traditional drugs of abuse, grown and distributed in bulk, have been disrupted” by the pandemic, he said in an interview. Although it may be too early for such cases to appear in Centers for Disease Control and Prevention reports, they can be described in studies like this one and, “I suspect, sadly, in medical examiner case reports.”
Flualprazolam, known colloquially as Hulk, is structurally related to the Food and Drug Administration–approved drugs alprazolam and triazolam. During 1 week in June 2019, the patients in Oregon received the drug as a free sample from another student from their Oregon high school. They believed it was commercial Xanax (alprazolam). “The flualprazolam tablets were identical in appearance and labeling to 2-mg tablets of alprazolam,” according to the report. “This indicates an intentionally counterfeit product entering the drug supply chain.”
Five of the six patients were boys, and they ranged in age from 14 to 16 years. The patient with mild respiratory depression received 0.4-mg naloxone, which physicians gave empirically because of the unknown identity of the drug, but did not respond. Two of the six patients initially felt drowsy but were asymptomatic during the clinical evaluation.
A urine immunoassay was performed in five of the patients, and all tested positive for benzodiazepines. One patient also tested positive for cannabinoids. Analysis of a tablet fragment revealed that it contained flualprazolam.
“Although flualprazolam intoxication cannot be clinically differentiated from that of other benzodiazepines without advanced testing, patient management should be the same,” Dr. Blumenberg and coauthors said. “For mild to moderate intoxication, patients should be treated with close monitoring and supportive care until symptom resolution. The benzodiazepine antidote flumazenil may be considered a safe and effective antidote in pediatric patients with significant CNS or respiratory depression. In patients for whom there is a concern of benzodiazepine dependence and flumazenil-induced seizures, airway protection and mechanical ventilation may be considered.”
Although patients rarely die from isolated benzodiazepine toxicity, death from respiratory depression or aspiration is more common when benzodiazepine toxicity occurs “in combination with alcohol, opioids, or other sedatives,” the authors noted. In addition, counterfeit alprazolam tablets have contained adulterants such as fentanyl and the opioid U-47700, which can be deadly.
The authors had no relevant financial disclosures, and there was no external funding for the study.
SOURCE: Blumenberg A et al. Pediatrics. 2020 Jun 24. doi: 10.1542/peds.2019-2953.
FROM PEDIATRICS
Could jump in opioid overdoses be linked to COVID?
Early evidence suggests that opioid overdoses and deaths are on the rise this year, the director of the National Institute on Drug Abuse warned colleagues, although it’s not clear whether the coronavirus pandemic is responsible for the trend.
The picture is complicated since COVID-19 could have both positive and negative effects on substance use, Nora D. Volkow, MD, said in a plenary session at the virtual annual meeting of the College on Problems of Drug Dependence. However, she said, one thing is clear: The pandemic marks an opportunity to investigate new strategies and potentially reform treatment.
“We are being faced with an unknown world, and the lack of information curtails our capacity to implement interventions in the most effective way,” Dr. Volkow said. “There’s an urgency to obtain these data. All of you out there in the trenches have an opportunity to help gather this information in a way that can be integrated and deployed rapidly for us to guide practices and treatment.”
It’s too early to know for certain how the pandemic is affecting substance use in the United States, since statistics are sparse and COVID-19 is still relatively new. Still, local news reports have suggested overdose deaths have risen, Dr. Volkow said.
And, she noted, the Office of National Drug Control Policy’s Overdose Detection Mapping Application Program – which tracks overdoses nationwide – issued 191% more “spike alerts” from January to April this year, compared with the same time period in 2019. However, the spike alerts started going up in January, several weeks before mass numbers of COVID-19 cases began to be diagnosed.
Dr. Volkow noted the uncertainty about the numbers but said several factors could cause the pandemic to boost overdoses:
- Stress and isolation. “My first fear was that overdoses are going to go up because the stress is actually extraordinarily difficult,” she said. “Social distancing is making it very difficult for individuals with substance use disorder or opioid use disorder to get the community support that keeps them from relapsing,” such as methadone clinics and syringe exchange programs.
- Unwitnessed opioid overdoses. Social distancing could “lead to overdoses that nobody has observed, so no one can administer naloxone,” she said.
- Treatment decisions affected by stigma. “Our health systems will be overburdened, and they have to make decisions about which patients to treat,” she said. Stigma could play a very important role in interfering with the treatment of individuals with substance use disorders.”
- Drug-related vulnerabilities. On another front, she said, substance users may be especially vulnerable to the pandemic, because the drugs target multiple body systems that worsen COVID-19 outcomes. These include not only the lungs but also the cardiac and metabolic systems, she said.
For example, “if you have a long history of drug use, you’re going to be much more likely to have a pulmonary disease,” she said. “We know that pulmonary disease is a risk factor for getting COVID and for much worse outcomes.”
But the pandemic could also help in the fight against substance use. For one thing, she said, the pandemic could disrupt drug markets and make it harder for users to get illicit products.
In yet another complication, there is an ongoing debate over whether tobacco use could actually be protective against COVID-19. Research into nicotine patches as a treatment is in the works, she said.
What now? Dr. Volkow said one priority going forward should be an evaluation of virtual medicine. “We have virtual technologies that have enabled us to do telemedicine to provide mental health support and hotlines, as well as virtual support meetings,” she said. “These have proliferated and have served to a certain extent to compensate for some of the deficit from the erosion of the community support systems that exist.”
Now, she said, we should evaluate which interventions are effective, which patients they help, and the components that make them work.
There are other opportunities for useful investigations, she said. For example, researchers could examine the effects of COVID-related changes in policy, such as the federal government allowing more methadone users to take doses home and expanded telemedicine policy allowing more remote prescriptions.
“If we can show that the outcomes are as good or better [than before] then we may be able to transform these practices that make it so very difficult for so many patients to get access to treatment and to sustain treatment – but have not been questioned for years and years.”
Dr. Volkow reported no relevant disclosures.
Early evidence suggests that opioid overdoses and deaths are on the rise this year, the director of the National Institute on Drug Abuse warned colleagues, although it’s not clear whether the coronavirus pandemic is responsible for the trend.
The picture is complicated since COVID-19 could have both positive and negative effects on substance use, Nora D. Volkow, MD, said in a plenary session at the virtual annual meeting of the College on Problems of Drug Dependence. However, she said, one thing is clear: The pandemic marks an opportunity to investigate new strategies and potentially reform treatment.
“We are being faced with an unknown world, and the lack of information curtails our capacity to implement interventions in the most effective way,” Dr. Volkow said. “There’s an urgency to obtain these data. All of you out there in the trenches have an opportunity to help gather this information in a way that can be integrated and deployed rapidly for us to guide practices and treatment.”
It’s too early to know for certain how the pandemic is affecting substance use in the United States, since statistics are sparse and COVID-19 is still relatively new. Still, local news reports have suggested overdose deaths have risen, Dr. Volkow said.
And, she noted, the Office of National Drug Control Policy’s Overdose Detection Mapping Application Program – which tracks overdoses nationwide – issued 191% more “spike alerts” from January to April this year, compared with the same time period in 2019. However, the spike alerts started going up in January, several weeks before mass numbers of COVID-19 cases began to be diagnosed.
Dr. Volkow noted the uncertainty about the numbers but said several factors could cause the pandemic to boost overdoses:
- Stress and isolation. “My first fear was that overdoses are going to go up because the stress is actually extraordinarily difficult,” she said. “Social distancing is making it very difficult for individuals with substance use disorder or opioid use disorder to get the community support that keeps them from relapsing,” such as methadone clinics and syringe exchange programs.
- Unwitnessed opioid overdoses. Social distancing could “lead to overdoses that nobody has observed, so no one can administer naloxone,” she said.
- Treatment decisions affected by stigma. “Our health systems will be overburdened, and they have to make decisions about which patients to treat,” she said. Stigma could play a very important role in interfering with the treatment of individuals with substance use disorders.”
- Drug-related vulnerabilities. On another front, she said, substance users may be especially vulnerable to the pandemic, because the drugs target multiple body systems that worsen COVID-19 outcomes. These include not only the lungs but also the cardiac and metabolic systems, she said.
For example, “if you have a long history of drug use, you’re going to be much more likely to have a pulmonary disease,” she said. “We know that pulmonary disease is a risk factor for getting COVID and for much worse outcomes.”
But the pandemic could also help in the fight against substance use. For one thing, she said, the pandemic could disrupt drug markets and make it harder for users to get illicit products.
In yet another complication, there is an ongoing debate over whether tobacco use could actually be protective against COVID-19. Research into nicotine patches as a treatment is in the works, she said.
What now? Dr. Volkow said one priority going forward should be an evaluation of virtual medicine. “We have virtual technologies that have enabled us to do telemedicine to provide mental health support and hotlines, as well as virtual support meetings,” she said. “These have proliferated and have served to a certain extent to compensate for some of the deficit from the erosion of the community support systems that exist.”
Now, she said, we should evaluate which interventions are effective, which patients they help, and the components that make them work.
There are other opportunities for useful investigations, she said. For example, researchers could examine the effects of COVID-related changes in policy, such as the federal government allowing more methadone users to take doses home and expanded telemedicine policy allowing more remote prescriptions.
“If we can show that the outcomes are as good or better [than before] then we may be able to transform these practices that make it so very difficult for so many patients to get access to treatment and to sustain treatment – but have not been questioned for years and years.”
Dr. Volkow reported no relevant disclosures.
Early evidence suggests that opioid overdoses and deaths are on the rise this year, the director of the National Institute on Drug Abuse warned colleagues, although it’s not clear whether the coronavirus pandemic is responsible for the trend.
The picture is complicated since COVID-19 could have both positive and negative effects on substance use, Nora D. Volkow, MD, said in a plenary session at the virtual annual meeting of the College on Problems of Drug Dependence. However, she said, one thing is clear: The pandemic marks an opportunity to investigate new strategies and potentially reform treatment.
“We are being faced with an unknown world, and the lack of information curtails our capacity to implement interventions in the most effective way,” Dr. Volkow said. “There’s an urgency to obtain these data. All of you out there in the trenches have an opportunity to help gather this information in a way that can be integrated and deployed rapidly for us to guide practices and treatment.”
It’s too early to know for certain how the pandemic is affecting substance use in the United States, since statistics are sparse and COVID-19 is still relatively new. Still, local news reports have suggested overdose deaths have risen, Dr. Volkow said.
And, she noted, the Office of National Drug Control Policy’s Overdose Detection Mapping Application Program – which tracks overdoses nationwide – issued 191% more “spike alerts” from January to April this year, compared with the same time period in 2019. However, the spike alerts started going up in January, several weeks before mass numbers of COVID-19 cases began to be diagnosed.
Dr. Volkow noted the uncertainty about the numbers but said several factors could cause the pandemic to boost overdoses:
- Stress and isolation. “My first fear was that overdoses are going to go up because the stress is actually extraordinarily difficult,” she said. “Social distancing is making it very difficult for individuals with substance use disorder or opioid use disorder to get the community support that keeps them from relapsing,” such as methadone clinics and syringe exchange programs.
- Unwitnessed opioid overdoses. Social distancing could “lead to overdoses that nobody has observed, so no one can administer naloxone,” she said.
- Treatment decisions affected by stigma. “Our health systems will be overburdened, and they have to make decisions about which patients to treat,” she said. Stigma could play a very important role in interfering with the treatment of individuals with substance use disorders.”
- Drug-related vulnerabilities. On another front, she said, substance users may be especially vulnerable to the pandemic, because the drugs target multiple body systems that worsen COVID-19 outcomes. These include not only the lungs but also the cardiac and metabolic systems, she said.
For example, “if you have a long history of drug use, you’re going to be much more likely to have a pulmonary disease,” she said. “We know that pulmonary disease is a risk factor for getting COVID and for much worse outcomes.”
But the pandemic could also help in the fight against substance use. For one thing, she said, the pandemic could disrupt drug markets and make it harder for users to get illicit products.
In yet another complication, there is an ongoing debate over whether tobacco use could actually be protective against COVID-19. Research into nicotine patches as a treatment is in the works, she said.
What now? Dr. Volkow said one priority going forward should be an evaluation of virtual medicine. “We have virtual technologies that have enabled us to do telemedicine to provide mental health support and hotlines, as well as virtual support meetings,” she said. “These have proliferated and have served to a certain extent to compensate for some of the deficit from the erosion of the community support systems that exist.”
Now, she said, we should evaluate which interventions are effective, which patients they help, and the components that make them work.
There are other opportunities for useful investigations, she said. For example, researchers could examine the effects of COVID-related changes in policy, such as the federal government allowing more methadone users to take doses home and expanded telemedicine policy allowing more remote prescriptions.
“If we can show that the outcomes are as good or better [than before] then we may be able to transform these practices that make it so very difficult for so many patients to get access to treatment and to sustain treatment – but have not been questioned for years and years.”
Dr. Volkow reported no relevant disclosures.
FROM CPDD 2020
What’s pushing cannabis use in first-episode psychosis?
The desire to feel better is a major driver for patients with first-episode psychosis (FEP) to turn to cannabis, new research shows.
An analysis of more than 1,300 individuals from six European countries showed patients with FEP were four times more likely than their healthy peers to start smoking cannabis in order to make themselves feel better.
The results also revealed that initiating cannabis use to feel better was associated with a more than tripled risk of being a daily user.
as well as offer an opportunity for psychoeducation – particularly as the reasons for starting cannabis appear to influence frequency of use, study investigator Edoardo Spinazzola, MD, Institute of Psychiatry, Psychology, and Neuroscience at King’s College London, said in an interview.
Patients who start smoking cannabis because their friends or family partakes may benefit from therapies that encourage more “assertiveness” and being “socially comfortable without the substance,” Dr. Spinazzola said, noting that it might also be beneficial to identify the specific cause of the psychological discomfort driving cannabis use, such as depression, and specifically treat that issue.
The results were scheduled to be presented at the Congress of the Schizophrenia International Research Society 2020, but the meeting was canceled because of the coronavirus pandemic.
Answering the skeptics
Previous studies suggest that cannabis use can increase risk for psychosis up to 290%, with both frequency of use and potency playing a role, the researchers noted.
However, they added that “skeptics” argue the association could be caused by individuals with psychosis using cannabis as a form of self-medication, the comorbid effect of other psychogenic drugs, or a common genetic vulnerability between cannabis use and psychosis.
The reasons for starting cannabis use remain “largely unexplored,” so the researchers examined records from the European network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) database, which includes patients with FEP and healthy individuals acting as controls from France, Italy, the Netherlands, Spain, United Kingdom, and Brazil.
The analysis included 1,347 individuals, of whom 446 had a diagnosis of nonaffective psychosis, 89 had bipolar disorder, and 58 had psychotic depression.
Reasons to start smoking cannabis and patterns of use were determined using the modified version of the Cannabis Experiences Questionnaire.
Results showed that participants who started cannabis to feel better were significantly more likely to be younger, have fewer years of education, to be black or of mixed ethnicity, to be single, or to not be living independently than those who started it because their friends or family were using it (P < .001 for all comparisons).
In addition, 68% of the patients with FEP and 85% of the healthy controls started using cannabis because friends or family were using it. In contrast, 18% of those with FEP versus 5% of controls starting using cannabis to feel better; 13% versus 10%, respectively, started using for “other reasons.”
After taking into account gender, age, ethnicity, and study site, the patients with FEP were significantly more likely than their healthy peers to have started using cannabis to feel better (relative risk ratio, 4.67; P < .001).
Starting to smoke cannabis to feel better versus any other reason was associated with an increased frequency of use in both those with and without FEP, with an RRR of 2.9 for using the drug more than once a week (P = .001) and an RRR of 3.13 for daily use (P < .001). However, the association was stronger in the healthy controls than in those with FEP, with an RRR for daily use of 4.45 versus 3.11, respectively.
The investigators also examined whether there was a link between reasons to start smoking and an individual’s polygenic risk score (PRS) for developing schizophrenia.
Multinomial regression indicated that PRS was not associated with starting cannabis to feel better or because friends were using it. However, there was an association between PRS score and starting the drug because family members were using it (RRR, 0.68; P < .05).
Complex association
Gabriella Gobbi, MD, PhD, professor in the neurobiological psychiatry unit, department of psychiatry, at McGill University, Montreal, said the data confirm “what we already know about cannabis.”
She noted that one of the “major causes” of young people starting cannabis is the social environment, while the desire to use the drug to feel better is linked to “the fact that cannabis, in a lot of cases, is used as a self-medication” in order to be calmer and as a relief from anxiety.
There is a “very complex” association between using cannabis to feel better and the self-medication seen with cigarette smoking and alcohol in patients with schizophrenia, said Dr. Gobbi, who was not involved with the research.
“When we talk about [patients using] cannabis, alcohol, and cigarettes, actually we’re talking about the same group of people,” she said.
Although “it is true they say that people look to cigarettes, tobacco, and alcohol to feel happier because they are depressed, the risk of psychosis is only for cannabis,” she added. “It is very low for alcohol and tobacco.”
As a result, Dr. Gobbi said she and her colleagues are “very worried” about the consequences for mental health of the legalization of cannabis consumption in Canada in October 2018 with the passing of the Cannabis Act.
Although there are no firm statistics yet, she has observed that since the law was passed, cannabis use has stabilized at a lower level among adolescents. “But now we have another population of people aged 34 and older that consume cannabis,” she said.
Particularly when considering the impact of higher strength cannabis on psychosis risk, Dr. Gobbi believes the increase in consumption in this age group will result in a “more elevated” risk for mental health issues.
Dr. Spinazzola and Dr. Gobbi have reported no relevant financial relationships.
A version of this article originally appeared on Medscape.com.
The desire to feel better is a major driver for patients with first-episode psychosis (FEP) to turn to cannabis, new research shows.
An analysis of more than 1,300 individuals from six European countries showed patients with FEP were four times more likely than their healthy peers to start smoking cannabis in order to make themselves feel better.
The results also revealed that initiating cannabis use to feel better was associated with a more than tripled risk of being a daily user.
as well as offer an opportunity for psychoeducation – particularly as the reasons for starting cannabis appear to influence frequency of use, study investigator Edoardo Spinazzola, MD, Institute of Psychiatry, Psychology, and Neuroscience at King’s College London, said in an interview.
Patients who start smoking cannabis because their friends or family partakes may benefit from therapies that encourage more “assertiveness” and being “socially comfortable without the substance,” Dr. Spinazzola said, noting that it might also be beneficial to identify the specific cause of the psychological discomfort driving cannabis use, such as depression, and specifically treat that issue.
The results were scheduled to be presented at the Congress of the Schizophrenia International Research Society 2020, but the meeting was canceled because of the coronavirus pandemic.
Answering the skeptics
Previous studies suggest that cannabis use can increase risk for psychosis up to 290%, with both frequency of use and potency playing a role, the researchers noted.
However, they added that “skeptics” argue the association could be caused by individuals with psychosis using cannabis as a form of self-medication, the comorbid effect of other psychogenic drugs, or a common genetic vulnerability between cannabis use and psychosis.
The reasons for starting cannabis use remain “largely unexplored,” so the researchers examined records from the European network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) database, which includes patients with FEP and healthy individuals acting as controls from France, Italy, the Netherlands, Spain, United Kingdom, and Brazil.
The analysis included 1,347 individuals, of whom 446 had a diagnosis of nonaffective psychosis, 89 had bipolar disorder, and 58 had psychotic depression.
Reasons to start smoking cannabis and patterns of use were determined using the modified version of the Cannabis Experiences Questionnaire.
Results showed that participants who started cannabis to feel better were significantly more likely to be younger, have fewer years of education, to be black or of mixed ethnicity, to be single, or to not be living independently than those who started it because their friends or family were using it (P < .001 for all comparisons).
In addition, 68% of the patients with FEP and 85% of the healthy controls started using cannabis because friends or family were using it. In contrast, 18% of those with FEP versus 5% of controls starting using cannabis to feel better; 13% versus 10%, respectively, started using for “other reasons.”
After taking into account gender, age, ethnicity, and study site, the patients with FEP were significantly more likely than their healthy peers to have started using cannabis to feel better (relative risk ratio, 4.67; P < .001).
Starting to smoke cannabis to feel better versus any other reason was associated with an increased frequency of use in both those with and without FEP, with an RRR of 2.9 for using the drug more than once a week (P = .001) and an RRR of 3.13 for daily use (P < .001). However, the association was stronger in the healthy controls than in those with FEP, with an RRR for daily use of 4.45 versus 3.11, respectively.
The investigators also examined whether there was a link between reasons to start smoking and an individual’s polygenic risk score (PRS) for developing schizophrenia.
Multinomial regression indicated that PRS was not associated with starting cannabis to feel better or because friends were using it. However, there was an association between PRS score and starting the drug because family members were using it (RRR, 0.68; P < .05).
Complex association
Gabriella Gobbi, MD, PhD, professor in the neurobiological psychiatry unit, department of psychiatry, at McGill University, Montreal, said the data confirm “what we already know about cannabis.”
She noted that one of the “major causes” of young people starting cannabis is the social environment, while the desire to use the drug to feel better is linked to “the fact that cannabis, in a lot of cases, is used as a self-medication” in order to be calmer and as a relief from anxiety.
There is a “very complex” association between using cannabis to feel better and the self-medication seen with cigarette smoking and alcohol in patients with schizophrenia, said Dr. Gobbi, who was not involved with the research.
“When we talk about [patients using] cannabis, alcohol, and cigarettes, actually we’re talking about the same group of people,” she said.
Although “it is true they say that people look to cigarettes, tobacco, and alcohol to feel happier because they are depressed, the risk of psychosis is only for cannabis,” she added. “It is very low for alcohol and tobacco.”
As a result, Dr. Gobbi said she and her colleagues are “very worried” about the consequences for mental health of the legalization of cannabis consumption in Canada in October 2018 with the passing of the Cannabis Act.
Although there are no firm statistics yet, she has observed that since the law was passed, cannabis use has stabilized at a lower level among adolescents. “But now we have another population of people aged 34 and older that consume cannabis,” she said.
Particularly when considering the impact of higher strength cannabis on psychosis risk, Dr. Gobbi believes the increase in consumption in this age group will result in a “more elevated” risk for mental health issues.
Dr. Spinazzola and Dr. Gobbi have reported no relevant financial relationships.
A version of this article originally appeared on Medscape.com.
The desire to feel better is a major driver for patients with first-episode psychosis (FEP) to turn to cannabis, new research shows.
An analysis of more than 1,300 individuals from six European countries showed patients with FEP were four times more likely than their healthy peers to start smoking cannabis in order to make themselves feel better.
The results also revealed that initiating cannabis use to feel better was associated with a more than tripled risk of being a daily user.
as well as offer an opportunity for psychoeducation – particularly as the reasons for starting cannabis appear to influence frequency of use, study investigator Edoardo Spinazzola, MD, Institute of Psychiatry, Psychology, and Neuroscience at King’s College London, said in an interview.
Patients who start smoking cannabis because their friends or family partakes may benefit from therapies that encourage more “assertiveness” and being “socially comfortable without the substance,” Dr. Spinazzola said, noting that it might also be beneficial to identify the specific cause of the psychological discomfort driving cannabis use, such as depression, and specifically treat that issue.
The results were scheduled to be presented at the Congress of the Schizophrenia International Research Society 2020, but the meeting was canceled because of the coronavirus pandemic.
Answering the skeptics
Previous studies suggest that cannabis use can increase risk for psychosis up to 290%, with both frequency of use and potency playing a role, the researchers noted.
However, they added that “skeptics” argue the association could be caused by individuals with psychosis using cannabis as a form of self-medication, the comorbid effect of other psychogenic drugs, or a common genetic vulnerability between cannabis use and psychosis.
The reasons for starting cannabis use remain “largely unexplored,” so the researchers examined records from the European network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) database, which includes patients with FEP and healthy individuals acting as controls from France, Italy, the Netherlands, Spain, United Kingdom, and Brazil.
The analysis included 1,347 individuals, of whom 446 had a diagnosis of nonaffective psychosis, 89 had bipolar disorder, and 58 had psychotic depression.
Reasons to start smoking cannabis and patterns of use were determined using the modified version of the Cannabis Experiences Questionnaire.
Results showed that participants who started cannabis to feel better were significantly more likely to be younger, have fewer years of education, to be black or of mixed ethnicity, to be single, or to not be living independently than those who started it because their friends or family were using it (P < .001 for all comparisons).
In addition, 68% of the patients with FEP and 85% of the healthy controls started using cannabis because friends or family were using it. In contrast, 18% of those with FEP versus 5% of controls starting using cannabis to feel better; 13% versus 10%, respectively, started using for “other reasons.”
After taking into account gender, age, ethnicity, and study site, the patients with FEP were significantly more likely than their healthy peers to have started using cannabis to feel better (relative risk ratio, 4.67; P < .001).
Starting to smoke cannabis to feel better versus any other reason was associated with an increased frequency of use in both those with and without FEP, with an RRR of 2.9 for using the drug more than once a week (P = .001) and an RRR of 3.13 for daily use (P < .001). However, the association was stronger in the healthy controls than in those with FEP, with an RRR for daily use of 4.45 versus 3.11, respectively.
The investigators also examined whether there was a link between reasons to start smoking and an individual’s polygenic risk score (PRS) for developing schizophrenia.
Multinomial regression indicated that PRS was not associated with starting cannabis to feel better or because friends were using it. However, there was an association between PRS score and starting the drug because family members were using it (RRR, 0.68; P < .05).
Complex association
Gabriella Gobbi, MD, PhD, professor in the neurobiological psychiatry unit, department of psychiatry, at McGill University, Montreal, said the data confirm “what we already know about cannabis.”
She noted that one of the “major causes” of young people starting cannabis is the social environment, while the desire to use the drug to feel better is linked to “the fact that cannabis, in a lot of cases, is used as a self-medication” in order to be calmer and as a relief from anxiety.
There is a “very complex” association between using cannabis to feel better and the self-medication seen with cigarette smoking and alcohol in patients with schizophrenia, said Dr. Gobbi, who was not involved with the research.
“When we talk about [patients using] cannabis, alcohol, and cigarettes, actually we’re talking about the same group of people,” she said.
Although “it is true they say that people look to cigarettes, tobacco, and alcohol to feel happier because they are depressed, the risk of psychosis is only for cannabis,” she added. “It is very low for alcohol and tobacco.”
As a result, Dr. Gobbi said she and her colleagues are “very worried” about the consequences for mental health of the legalization of cannabis consumption in Canada in October 2018 with the passing of the Cannabis Act.
Although there are no firm statistics yet, she has observed that since the law was passed, cannabis use has stabilized at a lower level among adolescents. “But now we have another population of people aged 34 and older that consume cannabis,” she said.
Particularly when considering the impact of higher strength cannabis on psychosis risk, Dr. Gobbi believes the increase in consumption in this age group will result in a “more elevated” risk for mental health issues.
Dr. Spinazzola and Dr. Gobbi have reported no relevant financial relationships.
A version of this article originally appeared on Medscape.com.
FROM SIRS 2020
Former smokers using e-cigarettes at risk for cigarette smoking relapse
The use of , results from a large longitudinal cohort study demonstrated.
“For the many clinicians treating former smokers who have successfully quit all nicotine products, the implications are that use of [electronic nicotine delivery systems] should be discouraged, just as use of all other tobacco products is discouraged,” researchers led by Colm D. Everard, PhD, reported in a study published in JAMA Network Open (2020 Jun 5. doi: 10.1001/jamanetworkopen.2020.4813).
Dr. Everard, of the National Institute on Drug Abuse, and colleagues based their comments on results from a survey of adult former smokers who participated in Waves 1-4 of the Population Assessment of Tobacco and Health (PATH) Study (2013-2018). They limited the analysis to 2,273 former cigarette smokers who self-reported reported no tobacco product use at Wave 1, and categorized them as recent former smokers (defined as having last smoked within the past 12 previous months) or as long-term former smokers (defined as having last smoked for longer ago than in the previous 12 months). The main outcome of interest was the self-reported current use of cigarettes at follow-up interviews, which was defined as every day or some days. Electronic nicotine delivery systems (ENDS) comprised e-cigarettes, e-cigars, e-pipes, and e-hookahs. Other tobacco products included cigars, pipe tobacco, hookahs, snus tobacco, other smokeless tobacco, and dissolvable tobacco.
Of the 2,273 adult former smokers, 52% were women, 60% were older than age 50, and 80% were non-Hispanic white. Adjusted hazard ratio (AHR) analysis revealed that the use of ENDS was associated with significant risk of cigarette smoking relapse among recent former smokers (AHR 1.63) and among long-term former smokers (AHR 3.79). The use of other tobacco products was associated with significant risk for cigarette smoking relapse among recent former smokers (AHR 1.97) and among long-term former smokers (AHR 3.82).
The authors acknowledged certain limitations of the study, including the fact that it did not assess different ENDS devices, different e-liquid nicotine levels, or frequency of ENDS use and their associations with cigarette smoking relapse. It also did not explore the mechanism by which ENDS use may lead to reestablishing or reinforcing nicotine-seeking behavior among former cigarette users. “Determining pharmacologic, behavioral, or some other explanation for these findings may require laboratory-based research,” they wrote.
The PATH Study is supported with federal funds from the National Institute on Drug Abuse, the National Institutes of Health, and the Food and Drug Administration and Department of Health and Human Services under a contract to Westat. One of the study authors, Wilson M. Compton, MD, reported having long-term stock holdings in General Electric, 3M, and Pfizer. The other authors reported having no financial disclosures.
The use of , results from a large longitudinal cohort study demonstrated.
“For the many clinicians treating former smokers who have successfully quit all nicotine products, the implications are that use of [electronic nicotine delivery systems] should be discouraged, just as use of all other tobacco products is discouraged,” researchers led by Colm D. Everard, PhD, reported in a study published in JAMA Network Open (2020 Jun 5. doi: 10.1001/jamanetworkopen.2020.4813).
Dr. Everard, of the National Institute on Drug Abuse, and colleagues based their comments on results from a survey of adult former smokers who participated in Waves 1-4 of the Population Assessment of Tobacco and Health (PATH) Study (2013-2018). They limited the analysis to 2,273 former cigarette smokers who self-reported reported no tobacco product use at Wave 1, and categorized them as recent former smokers (defined as having last smoked within the past 12 previous months) or as long-term former smokers (defined as having last smoked for longer ago than in the previous 12 months). The main outcome of interest was the self-reported current use of cigarettes at follow-up interviews, which was defined as every day or some days. Electronic nicotine delivery systems (ENDS) comprised e-cigarettes, e-cigars, e-pipes, and e-hookahs. Other tobacco products included cigars, pipe tobacco, hookahs, snus tobacco, other smokeless tobacco, and dissolvable tobacco.
Of the 2,273 adult former smokers, 52% were women, 60% were older than age 50, and 80% were non-Hispanic white. Adjusted hazard ratio (AHR) analysis revealed that the use of ENDS was associated with significant risk of cigarette smoking relapse among recent former smokers (AHR 1.63) and among long-term former smokers (AHR 3.79). The use of other tobacco products was associated with significant risk for cigarette smoking relapse among recent former smokers (AHR 1.97) and among long-term former smokers (AHR 3.82).
The authors acknowledged certain limitations of the study, including the fact that it did not assess different ENDS devices, different e-liquid nicotine levels, or frequency of ENDS use and their associations with cigarette smoking relapse. It also did not explore the mechanism by which ENDS use may lead to reestablishing or reinforcing nicotine-seeking behavior among former cigarette users. “Determining pharmacologic, behavioral, or some other explanation for these findings may require laboratory-based research,” they wrote.
The PATH Study is supported with federal funds from the National Institute on Drug Abuse, the National Institutes of Health, and the Food and Drug Administration and Department of Health and Human Services under a contract to Westat. One of the study authors, Wilson M. Compton, MD, reported having long-term stock holdings in General Electric, 3M, and Pfizer. The other authors reported having no financial disclosures.
The use of , results from a large longitudinal cohort study demonstrated.
“For the many clinicians treating former smokers who have successfully quit all nicotine products, the implications are that use of [electronic nicotine delivery systems] should be discouraged, just as use of all other tobacco products is discouraged,” researchers led by Colm D. Everard, PhD, reported in a study published in JAMA Network Open (2020 Jun 5. doi: 10.1001/jamanetworkopen.2020.4813).
Dr. Everard, of the National Institute on Drug Abuse, and colleagues based their comments on results from a survey of adult former smokers who participated in Waves 1-4 of the Population Assessment of Tobacco and Health (PATH) Study (2013-2018). They limited the analysis to 2,273 former cigarette smokers who self-reported reported no tobacco product use at Wave 1, and categorized them as recent former smokers (defined as having last smoked within the past 12 previous months) or as long-term former smokers (defined as having last smoked for longer ago than in the previous 12 months). The main outcome of interest was the self-reported current use of cigarettes at follow-up interviews, which was defined as every day or some days. Electronic nicotine delivery systems (ENDS) comprised e-cigarettes, e-cigars, e-pipes, and e-hookahs. Other tobacco products included cigars, pipe tobacco, hookahs, snus tobacco, other smokeless tobacco, and dissolvable tobacco.
Of the 2,273 adult former smokers, 52% were women, 60% were older than age 50, and 80% were non-Hispanic white. Adjusted hazard ratio (AHR) analysis revealed that the use of ENDS was associated with significant risk of cigarette smoking relapse among recent former smokers (AHR 1.63) and among long-term former smokers (AHR 3.79). The use of other tobacco products was associated with significant risk for cigarette smoking relapse among recent former smokers (AHR 1.97) and among long-term former smokers (AHR 3.82).
The authors acknowledged certain limitations of the study, including the fact that it did not assess different ENDS devices, different e-liquid nicotine levels, or frequency of ENDS use and their associations with cigarette smoking relapse. It also did not explore the mechanism by which ENDS use may lead to reestablishing or reinforcing nicotine-seeking behavior among former cigarette users. “Determining pharmacologic, behavioral, or some other explanation for these findings may require laboratory-based research,” they wrote.
The PATH Study is supported with federal funds from the National Institute on Drug Abuse, the National Institutes of Health, and the Food and Drug Administration and Department of Health and Human Services under a contract to Westat. One of the study authors, Wilson M. Compton, MD, reported having long-term stock holdings in General Electric, 3M, and Pfizer. The other authors reported having no financial disclosures.
FROM JAMA NETWORK OPEN
Irritability strongly linked to suicidal behavior in major depression
Irritability in adults with major depressive disorder (MDD) and stimulant use disorder (SUD) is strongly linked to suicidality and should be assessed by clinicians.
Three clinical trials of adults with MDD and one trial of adults with SUD showed that the link between irritability and suicidality was stronger than the association between depression severity and suicidal behaviors.
“Irritability is an important construct that is not often studied in adults with major depressive disorder,” Manish K. Jha, MD, of Icahn School of Medicine at Mount Sinai, New York, said in an interview.
“If you look at current diagnostic convention, irritability is not considered a symptom of major depressive episodes in adults, but below age 18, it is considered one of the two main symptoms,” Dr. Jha said.
The findings were presented at the virtual American Society of Clinical Psychopharmacology 2020 annual Meeting.
Clinically useful
Irritability is assessed using age-related norms of behavior, Dr. Jha said.
“The best way to conceptualize it is that it is the propensity to get angry easily or more frequently as compared to peers in response to frustration. I have a 2½-year old, and if he throws a tantrum, that is perfectly age appropriate. But if I do the same thing, it would be extreme irritability. The pediatric literature uses the word ‘grouchiness,’ but it is a little bit difficult to define, in part because it hasn’t been studied extensively,” he said.
To better understand the potential association between irritability and suicidality, the investigators reviewed results of three trials involving adults with MDD. These trials were CO-MED (Combining Medications to Enhance Depression Outcomes), which included 665 patients; EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care), which included 296 patients; and SAMS (Suicide Assessment Methodology Study), which included 266 patients.
They also examined the STRIDE (Stimulant Reduction Intervention Using Dosed Exercise) study, which was conducted in 302 adults with SUD.
All studies assessed irritability using the Concise Associated Symptom Tracking scale, a 5-point Likert scale. The trials also assessed suicidality with the Concise Health Risk Tracking Suicidal Thoughts.
The investigators found that irritability and suicidality were positively correlated. The association between irritability and suicidality was 2-11 times stronger than the link to overall depression.
Higher irritability at baseline predicted higher levels of suicidality at week 9 in CO-MED (P = .011), EMBARC (P < .0001), and STRIDE (P = .007), but not in SAMS (P = .21).
Greater reduction in irritability from baseline to week 4 predicted lower levels of suicidality at week 8 in CO-MED (P = .007), EMBARC (P < .0001), and STRIDE (P < .0001), but not in SAMS (P = .065).
Similarly, lower baseline levels and greater reductions in irritability were associated with lower levels of suicidality at week 28 of CO-MED, week 16 of EMBARC, and week 36 of STRIDE.
, and he believes that measuring irritability in MDD “has clinical utility.”
A common and disabling symptom
Commenting on the study, Sanjay J. Mathew, MD, professor of psychiatry and behavioral sciences at Baylor College of Medicine, Houston, said the findings provide further support that irritability is a relatively common and disabling symptom associated with major depression.
“The presence of significant irritability was associated with higher levels of suicidal ideation and is therefore highly relevant for clinicians to assess,” said Dr. Mathew, who was not part of the study.
“Early improvements in irritability are associated with better longer-term outcomes with antidepressant treatments, and this highlights the need for careful clinical evaluation early on in the course of antidepressant therapy, ideally within the first 2 weeks,” he said.
Dr. Jha reports financial relationships with Acadia Pharmaceuticals and Janssen Research & Development. Dr. Mathew reports financial relationships with Allergan, Vistagen, Janssen, Clexio, and Biohaven.
A version of this article originally appeared on Medscape.com.
Irritability in adults with major depressive disorder (MDD) and stimulant use disorder (SUD) is strongly linked to suicidality and should be assessed by clinicians.
Three clinical trials of adults with MDD and one trial of adults with SUD showed that the link between irritability and suicidality was stronger than the association between depression severity and suicidal behaviors.
“Irritability is an important construct that is not often studied in adults with major depressive disorder,” Manish K. Jha, MD, of Icahn School of Medicine at Mount Sinai, New York, said in an interview.
“If you look at current diagnostic convention, irritability is not considered a symptom of major depressive episodes in adults, but below age 18, it is considered one of the two main symptoms,” Dr. Jha said.
The findings were presented at the virtual American Society of Clinical Psychopharmacology 2020 annual Meeting.
Clinically useful
Irritability is assessed using age-related norms of behavior, Dr. Jha said.
“The best way to conceptualize it is that it is the propensity to get angry easily or more frequently as compared to peers in response to frustration. I have a 2½-year old, and if he throws a tantrum, that is perfectly age appropriate. But if I do the same thing, it would be extreme irritability. The pediatric literature uses the word ‘grouchiness,’ but it is a little bit difficult to define, in part because it hasn’t been studied extensively,” he said.
To better understand the potential association between irritability and suicidality, the investigators reviewed results of three trials involving adults with MDD. These trials were CO-MED (Combining Medications to Enhance Depression Outcomes), which included 665 patients; EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care), which included 296 patients; and SAMS (Suicide Assessment Methodology Study), which included 266 patients.
They also examined the STRIDE (Stimulant Reduction Intervention Using Dosed Exercise) study, which was conducted in 302 adults with SUD.
All studies assessed irritability using the Concise Associated Symptom Tracking scale, a 5-point Likert scale. The trials also assessed suicidality with the Concise Health Risk Tracking Suicidal Thoughts.
The investigators found that irritability and suicidality were positively correlated. The association between irritability and suicidality was 2-11 times stronger than the link to overall depression.
Higher irritability at baseline predicted higher levels of suicidality at week 9 in CO-MED (P = .011), EMBARC (P < .0001), and STRIDE (P = .007), but not in SAMS (P = .21).
Greater reduction in irritability from baseline to week 4 predicted lower levels of suicidality at week 8 in CO-MED (P = .007), EMBARC (P < .0001), and STRIDE (P < .0001), but not in SAMS (P = .065).
Similarly, lower baseline levels and greater reductions in irritability were associated with lower levels of suicidality at week 28 of CO-MED, week 16 of EMBARC, and week 36 of STRIDE.
, and he believes that measuring irritability in MDD “has clinical utility.”
A common and disabling symptom
Commenting on the study, Sanjay J. Mathew, MD, professor of psychiatry and behavioral sciences at Baylor College of Medicine, Houston, said the findings provide further support that irritability is a relatively common and disabling symptom associated with major depression.
“The presence of significant irritability was associated with higher levels of suicidal ideation and is therefore highly relevant for clinicians to assess,” said Dr. Mathew, who was not part of the study.
“Early improvements in irritability are associated with better longer-term outcomes with antidepressant treatments, and this highlights the need for careful clinical evaluation early on in the course of antidepressant therapy, ideally within the first 2 weeks,” he said.
Dr. Jha reports financial relationships with Acadia Pharmaceuticals and Janssen Research & Development. Dr. Mathew reports financial relationships with Allergan, Vistagen, Janssen, Clexio, and Biohaven.
A version of this article originally appeared on Medscape.com.
Irritability in adults with major depressive disorder (MDD) and stimulant use disorder (SUD) is strongly linked to suicidality and should be assessed by clinicians.
Three clinical trials of adults with MDD and one trial of adults with SUD showed that the link between irritability and suicidality was stronger than the association between depression severity and suicidal behaviors.
“Irritability is an important construct that is not often studied in adults with major depressive disorder,” Manish K. Jha, MD, of Icahn School of Medicine at Mount Sinai, New York, said in an interview.
“If you look at current diagnostic convention, irritability is not considered a symptom of major depressive episodes in adults, but below age 18, it is considered one of the two main symptoms,” Dr. Jha said.
The findings were presented at the virtual American Society of Clinical Psychopharmacology 2020 annual Meeting.
Clinically useful
Irritability is assessed using age-related norms of behavior, Dr. Jha said.
“The best way to conceptualize it is that it is the propensity to get angry easily or more frequently as compared to peers in response to frustration. I have a 2½-year old, and if he throws a tantrum, that is perfectly age appropriate. But if I do the same thing, it would be extreme irritability. The pediatric literature uses the word ‘grouchiness,’ but it is a little bit difficult to define, in part because it hasn’t been studied extensively,” he said.
To better understand the potential association between irritability and suicidality, the investigators reviewed results of three trials involving adults with MDD. These trials were CO-MED (Combining Medications to Enhance Depression Outcomes), which included 665 patients; EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care), which included 296 patients; and SAMS (Suicide Assessment Methodology Study), which included 266 patients.
They also examined the STRIDE (Stimulant Reduction Intervention Using Dosed Exercise) study, which was conducted in 302 adults with SUD.
All studies assessed irritability using the Concise Associated Symptom Tracking scale, a 5-point Likert scale. The trials also assessed suicidality with the Concise Health Risk Tracking Suicidal Thoughts.
The investigators found that irritability and suicidality were positively correlated. The association between irritability and suicidality was 2-11 times stronger than the link to overall depression.
Higher irritability at baseline predicted higher levels of suicidality at week 9 in CO-MED (P = .011), EMBARC (P < .0001), and STRIDE (P = .007), but not in SAMS (P = .21).
Greater reduction in irritability from baseline to week 4 predicted lower levels of suicidality at week 8 in CO-MED (P = .007), EMBARC (P < .0001), and STRIDE (P < .0001), but not in SAMS (P = .065).
Similarly, lower baseline levels and greater reductions in irritability were associated with lower levels of suicidality at week 28 of CO-MED, week 16 of EMBARC, and week 36 of STRIDE.
, and he believes that measuring irritability in MDD “has clinical utility.”
A common and disabling symptom
Commenting on the study, Sanjay J. Mathew, MD, professor of psychiatry and behavioral sciences at Baylor College of Medicine, Houston, said the findings provide further support that irritability is a relatively common and disabling symptom associated with major depression.
“The presence of significant irritability was associated with higher levels of suicidal ideation and is therefore highly relevant for clinicians to assess,” said Dr. Mathew, who was not part of the study.
“Early improvements in irritability are associated with better longer-term outcomes with antidepressant treatments, and this highlights the need for careful clinical evaluation early on in the course of antidepressant therapy, ideally within the first 2 weeks,” he said.
Dr. Jha reports financial relationships with Acadia Pharmaceuticals and Janssen Research & Development. Dr. Mathew reports financial relationships with Allergan, Vistagen, Janssen, Clexio, and Biohaven.
A version of this article originally appeared on Medscape.com.
NIMH strategic plan returns balance to research priorities
Digital health, suicide prevention, innovation addressed
The National Institute of Mental Health’s 2020 Strategic Plan outlines priorities in basic science research and clinical trials for psychiatry over the next 5 years, emphasizing where advances are needed in suicide prevention, digital health technology, early diagnosis in psychosis, and much more.
Experts’ reaction to the strategic plan is mixed. Some applaud the NIMH for addressing many essential research priorities and for returning a balance to the focus on basic/translational research and clinical advances. Others would have liked to see a different emphasis on some components of the plan.
Focusing on diversity
A greater weight on research in diverse populations and a renewed focus on studies across the lifespan – including developmental origins of psychiatric illness – are among the novel aspects of the plan.
“The enhanced attention to recruiting diverse subjects and focusing on diversity in our research is new and very welcome,” Jonathan E. Alpert, MD, PhD, chair of the American Psychiatric Association’s Council on Research, said in an interview.
Addressing the entire lifespan is likewise important, added Dr. Alpert, who holds the Dorothy and Marty Silverman Chair of Psychiatry at the Albert Einstein College of Medicine in New York. “Many of the conditions we treat – whether they are mood disorders or even dementia– might have developmental origins that would be best studied early in life.”
Furthermore, the plan promotes more interdisciplinary collaboration. For example, there are new cross-cutting research themes, including prevention, environmental influences, global health, and more. These are areas where psychiatry needs strengthening, said Stevan M. Weine, MD, director of Global Medicine at the University of Illinois at Chicago, in an interview.
In the era of COVID-19, which will involve ongoing diseases and disasters such as those tied to climate changes and disparities, there will be a need to conduct research and train researchers who are more open to new research questions, said Dr. Weine, also director of the Center for Global Health and professor of psychiatry at the university. It also will be important to partner with researchers from multiple disciplines, he added.
The plan also recognizes novel applications of digital technology. In addition, the plan outlines the promise of “harnessing the power of data,” such as machine learning, to help identify suicide risk factors based on large data, for example. However, Igor Galynker, MD, PhD, predicted that this technology will likely identify factors that “we see again and again,” such as depression, other forms of mental illness, and previous attempt history.
“Machine learning is useful but should not be emphasized” even if it is “technologically sexy and almost seductive,” Dr. Galynker, director of the Suicide Research & Prevention Laboratory at the Icahn School of Medicine at Mount Sinai in New York, said in an interview.
Addressing suicide
The strategic plan places a renewed emphasis on suicide prevention. The report cites a “troubling rise in the national suicide rate.” The authors suggested expanding initial success with brief screening tools in emergency departments to other clinical settings. Furthermore, the report highlights evidence that pairing such screening with low-cost follow-up interventions, such as telephone calls, can reduce the number of suicide attempts the following year.
Widespread screening could help identify people at risk, but it relies on the honesty of self-reporting, Dr. Galynker said, adding that about 75% of people who end their own lives never disclose their plan to anyone. Furthermore, suicide intent can be very short-lived – a crisis lasting as little as 15 minutes for some – reducing the likelihood that routine screening will flag a person in crisis.
“What is missing is an individual approach,” Dr. Galynker said while also endorsing the systemic approach to suicide prevention in the plan. “One thing in the strategic plan I may not agree with is the emphasis on administrative prediction measures ... based on drop-down menus and risk factors, and not on patient stories.” Risk factors are useful for long-term or lifetime risk, but they are not going to predict who will switch to acute suicidal state in the next several days or hours.”
Instead, Dr. Galynker suggested screening people for suicide crisis syndrome, which is “a very defined, characteristic, reproducible, and importantly, treatable,” state.
Covering basic neuroscience
Suicide prevention is just one of seven challenges and opportunities highlighted in the strategic plan. The authors also address research priorities for early treatment of psychosis and for research into mental health equity, HIV/AIDS research, genetics, and neural circuits.
“My overall impression is it’s very positive,” said Dr. Alpert, who is also professor and chair of the psychiatry and behavioral sciences department at Albert Einstein. “It really spans basic and translational neuroscience all the way to health services research and health disparities research. And I think, for many of us, we welcome that. It feels very relevant to the broad span of meaningful psychiatric research.”
Dr. Weine agreed. The strategic plan is “very helpful,” he said. “It is comprehensive, broad, and multidisciplinary.”
Promoting four overall goals
The plan seeks to promote the four following goals:
- Define the brain mechanisms underlying complex behaviors.
- Examine mental illness trajectories across the lifespan.
- Strive for prevention and cures.
- Strengthen the public health effects of National Institutes of Health–supported research.
The first goal is “an effort to try to make sense of the underlying biology, and that has to be your foundation point,” Ken Duckworth, MD, chief medical officer at the National Alliance on Mental Illness in Arlington, Va., said in an interview. “The reason we don’t have a lot of new drug discovery is because the fundamentals of biology still need understanding. It’s a long-term goal, so it’s hard,” he added. “Everyone living with someone in their life with an illness wants better ideas now.”
The third goal is likewise challenging, Dr. Duckworth said. “That is optimistic and ... aspirational, but very important and valuable.”
Developing innovative models
Regarding the public health goal, Dr. Duckworth cited one of the objectives, to “Develop innovative service delivery models to dramatically improve the outcomes of mental health services received in diverse communities and populations.” Dr. Duckworth explained, “Trying to solve for the problem in the context of an inadequate workforce that is insufficiently diverse – it just gets to something that I’m not sure would have been a priority in the past.
“That speaks to the awakening we’re having as a society. To address some of these historic and systemic injustices and how research can play into that is really important,” Dr. Duckworth added.
Overall, he saluted the plan and its goals. Dr. Duckworth added, “We gave some feedback that we wanted more emphasis on co-occurring disorders, such as research into people with mental health and addiction [issues] and on premature mortality. I think they took some of that feedback.”
Facing ‘significant challenges’
Dr. Weine added. “It sets a path for scientific advances that are responsive to these problems.”
“The future is bright. Looking forward to the next 5 years and beyond, the new NIMH Strategic Plan for Research aims to build on these advances,” Joshua A. Gordon, MD, PhD, NIMH director, noted in his Director’s Messages blog.
“Nonetheless, we face significant challenges,” he adds. “Studies of the origins of mental illnesses suggest that a combination of causes – genetic, environmental, social, and psychological – act on the brain through a complex web of interactions, resulting in a set of heterogeneous and overlapping illnesses.”
“My hope is that the actual funding of research over the coming years reflects the comprehensive, broad, and multidisciplinary characteristics of this strategic plan,” Dr. Weine said.
The NIMH plans to its post progress for each goal on an ongoing basis on the Strategic Plan website.
Dr. Alpert, Dr. Galynker, Dr. Weine, and Dr. Duckworth had no relevant disclosures.
Digital health, suicide prevention, innovation addressed
Digital health, suicide prevention, innovation addressed
The National Institute of Mental Health’s 2020 Strategic Plan outlines priorities in basic science research and clinical trials for psychiatry over the next 5 years, emphasizing where advances are needed in suicide prevention, digital health technology, early diagnosis in psychosis, and much more.
Experts’ reaction to the strategic plan is mixed. Some applaud the NIMH for addressing many essential research priorities and for returning a balance to the focus on basic/translational research and clinical advances. Others would have liked to see a different emphasis on some components of the plan.
Focusing on diversity
A greater weight on research in diverse populations and a renewed focus on studies across the lifespan – including developmental origins of psychiatric illness – are among the novel aspects of the plan.
“The enhanced attention to recruiting diverse subjects and focusing on diversity in our research is new and very welcome,” Jonathan E. Alpert, MD, PhD, chair of the American Psychiatric Association’s Council on Research, said in an interview.
Addressing the entire lifespan is likewise important, added Dr. Alpert, who holds the Dorothy and Marty Silverman Chair of Psychiatry at the Albert Einstein College of Medicine in New York. “Many of the conditions we treat – whether they are mood disorders or even dementia– might have developmental origins that would be best studied early in life.”
Furthermore, the plan promotes more interdisciplinary collaboration. For example, there are new cross-cutting research themes, including prevention, environmental influences, global health, and more. These are areas where psychiatry needs strengthening, said Stevan M. Weine, MD, director of Global Medicine at the University of Illinois at Chicago, in an interview.
In the era of COVID-19, which will involve ongoing diseases and disasters such as those tied to climate changes and disparities, there will be a need to conduct research and train researchers who are more open to new research questions, said Dr. Weine, also director of the Center for Global Health and professor of psychiatry at the university. It also will be important to partner with researchers from multiple disciplines, he added.
The plan also recognizes novel applications of digital technology. In addition, the plan outlines the promise of “harnessing the power of data,” such as machine learning, to help identify suicide risk factors based on large data, for example. However, Igor Galynker, MD, PhD, predicted that this technology will likely identify factors that “we see again and again,” such as depression, other forms of mental illness, and previous attempt history.
“Machine learning is useful but should not be emphasized” even if it is “technologically sexy and almost seductive,” Dr. Galynker, director of the Suicide Research & Prevention Laboratory at the Icahn School of Medicine at Mount Sinai in New York, said in an interview.
Addressing suicide
The strategic plan places a renewed emphasis on suicide prevention. The report cites a “troubling rise in the national suicide rate.” The authors suggested expanding initial success with brief screening tools in emergency departments to other clinical settings. Furthermore, the report highlights evidence that pairing such screening with low-cost follow-up interventions, such as telephone calls, can reduce the number of suicide attempts the following year.
Widespread screening could help identify people at risk, but it relies on the honesty of self-reporting, Dr. Galynker said, adding that about 75% of people who end their own lives never disclose their plan to anyone. Furthermore, suicide intent can be very short-lived – a crisis lasting as little as 15 minutes for some – reducing the likelihood that routine screening will flag a person in crisis.
“What is missing is an individual approach,” Dr. Galynker said while also endorsing the systemic approach to suicide prevention in the plan. “One thing in the strategic plan I may not agree with is the emphasis on administrative prediction measures ... based on drop-down menus and risk factors, and not on patient stories.” Risk factors are useful for long-term or lifetime risk, but they are not going to predict who will switch to acute suicidal state in the next several days or hours.”
Instead, Dr. Galynker suggested screening people for suicide crisis syndrome, which is “a very defined, characteristic, reproducible, and importantly, treatable,” state.
Covering basic neuroscience
Suicide prevention is just one of seven challenges and opportunities highlighted in the strategic plan. The authors also address research priorities for early treatment of psychosis and for research into mental health equity, HIV/AIDS research, genetics, and neural circuits.
“My overall impression is it’s very positive,” said Dr. Alpert, who is also professor and chair of the psychiatry and behavioral sciences department at Albert Einstein. “It really spans basic and translational neuroscience all the way to health services research and health disparities research. And I think, for many of us, we welcome that. It feels very relevant to the broad span of meaningful psychiatric research.”
Dr. Weine agreed. The strategic plan is “very helpful,” he said. “It is comprehensive, broad, and multidisciplinary.”
Promoting four overall goals
The plan seeks to promote the four following goals:
- Define the brain mechanisms underlying complex behaviors.
- Examine mental illness trajectories across the lifespan.
- Strive for prevention and cures.
- Strengthen the public health effects of National Institutes of Health–supported research.
The first goal is “an effort to try to make sense of the underlying biology, and that has to be your foundation point,” Ken Duckworth, MD, chief medical officer at the National Alliance on Mental Illness in Arlington, Va., said in an interview. “The reason we don’t have a lot of new drug discovery is because the fundamentals of biology still need understanding. It’s a long-term goal, so it’s hard,” he added. “Everyone living with someone in their life with an illness wants better ideas now.”
The third goal is likewise challenging, Dr. Duckworth said. “That is optimistic and ... aspirational, but very important and valuable.”
Developing innovative models
Regarding the public health goal, Dr. Duckworth cited one of the objectives, to “Develop innovative service delivery models to dramatically improve the outcomes of mental health services received in diverse communities and populations.” Dr. Duckworth explained, “Trying to solve for the problem in the context of an inadequate workforce that is insufficiently diverse – it just gets to something that I’m not sure would have been a priority in the past.
“That speaks to the awakening we’re having as a society. To address some of these historic and systemic injustices and how research can play into that is really important,” Dr. Duckworth added.
Overall, he saluted the plan and its goals. Dr. Duckworth added, “We gave some feedback that we wanted more emphasis on co-occurring disorders, such as research into people with mental health and addiction [issues] and on premature mortality. I think they took some of that feedback.”
Facing ‘significant challenges’
Dr. Weine added. “It sets a path for scientific advances that are responsive to these problems.”
“The future is bright. Looking forward to the next 5 years and beyond, the new NIMH Strategic Plan for Research aims to build on these advances,” Joshua A. Gordon, MD, PhD, NIMH director, noted in his Director’s Messages blog.
“Nonetheless, we face significant challenges,” he adds. “Studies of the origins of mental illnesses suggest that a combination of causes – genetic, environmental, social, and psychological – act on the brain through a complex web of interactions, resulting in a set of heterogeneous and overlapping illnesses.”
“My hope is that the actual funding of research over the coming years reflects the comprehensive, broad, and multidisciplinary characteristics of this strategic plan,” Dr. Weine said.
The NIMH plans to its post progress for each goal on an ongoing basis on the Strategic Plan website.
Dr. Alpert, Dr. Galynker, Dr. Weine, and Dr. Duckworth had no relevant disclosures.
The National Institute of Mental Health’s 2020 Strategic Plan outlines priorities in basic science research and clinical trials for psychiatry over the next 5 years, emphasizing where advances are needed in suicide prevention, digital health technology, early diagnosis in psychosis, and much more.
Experts’ reaction to the strategic plan is mixed. Some applaud the NIMH for addressing many essential research priorities and for returning a balance to the focus on basic/translational research and clinical advances. Others would have liked to see a different emphasis on some components of the plan.
Focusing on diversity
A greater weight on research in diverse populations and a renewed focus on studies across the lifespan – including developmental origins of psychiatric illness – are among the novel aspects of the plan.
“The enhanced attention to recruiting diverse subjects and focusing on diversity in our research is new and very welcome,” Jonathan E. Alpert, MD, PhD, chair of the American Psychiatric Association’s Council on Research, said in an interview.
Addressing the entire lifespan is likewise important, added Dr. Alpert, who holds the Dorothy and Marty Silverman Chair of Psychiatry at the Albert Einstein College of Medicine in New York. “Many of the conditions we treat – whether they are mood disorders or even dementia– might have developmental origins that would be best studied early in life.”
Furthermore, the plan promotes more interdisciplinary collaboration. For example, there are new cross-cutting research themes, including prevention, environmental influences, global health, and more. These are areas where psychiatry needs strengthening, said Stevan M. Weine, MD, director of Global Medicine at the University of Illinois at Chicago, in an interview.
In the era of COVID-19, which will involve ongoing diseases and disasters such as those tied to climate changes and disparities, there will be a need to conduct research and train researchers who are more open to new research questions, said Dr. Weine, also director of the Center for Global Health and professor of psychiatry at the university. It also will be important to partner with researchers from multiple disciplines, he added.
The plan also recognizes novel applications of digital technology. In addition, the plan outlines the promise of “harnessing the power of data,” such as machine learning, to help identify suicide risk factors based on large data, for example. However, Igor Galynker, MD, PhD, predicted that this technology will likely identify factors that “we see again and again,” such as depression, other forms of mental illness, and previous attempt history.
“Machine learning is useful but should not be emphasized” even if it is “technologically sexy and almost seductive,” Dr. Galynker, director of the Suicide Research & Prevention Laboratory at the Icahn School of Medicine at Mount Sinai in New York, said in an interview.
Addressing suicide
The strategic plan places a renewed emphasis on suicide prevention. The report cites a “troubling rise in the national suicide rate.” The authors suggested expanding initial success with brief screening tools in emergency departments to other clinical settings. Furthermore, the report highlights evidence that pairing such screening with low-cost follow-up interventions, such as telephone calls, can reduce the number of suicide attempts the following year.
Widespread screening could help identify people at risk, but it relies on the honesty of self-reporting, Dr. Galynker said, adding that about 75% of people who end their own lives never disclose their plan to anyone. Furthermore, suicide intent can be very short-lived – a crisis lasting as little as 15 minutes for some – reducing the likelihood that routine screening will flag a person in crisis.
“What is missing is an individual approach,” Dr. Galynker said while also endorsing the systemic approach to suicide prevention in the plan. “One thing in the strategic plan I may not agree with is the emphasis on administrative prediction measures ... based on drop-down menus and risk factors, and not on patient stories.” Risk factors are useful for long-term or lifetime risk, but they are not going to predict who will switch to acute suicidal state in the next several days or hours.”
Instead, Dr. Galynker suggested screening people for suicide crisis syndrome, which is “a very defined, characteristic, reproducible, and importantly, treatable,” state.
Covering basic neuroscience
Suicide prevention is just one of seven challenges and opportunities highlighted in the strategic plan. The authors also address research priorities for early treatment of psychosis and for research into mental health equity, HIV/AIDS research, genetics, and neural circuits.
“My overall impression is it’s very positive,” said Dr. Alpert, who is also professor and chair of the psychiatry and behavioral sciences department at Albert Einstein. “It really spans basic and translational neuroscience all the way to health services research and health disparities research. And I think, for many of us, we welcome that. It feels very relevant to the broad span of meaningful psychiatric research.”
Dr. Weine agreed. The strategic plan is “very helpful,” he said. “It is comprehensive, broad, and multidisciplinary.”
Promoting four overall goals
The plan seeks to promote the four following goals:
- Define the brain mechanisms underlying complex behaviors.
- Examine mental illness trajectories across the lifespan.
- Strive for prevention and cures.
- Strengthen the public health effects of National Institutes of Health–supported research.
The first goal is “an effort to try to make sense of the underlying biology, and that has to be your foundation point,” Ken Duckworth, MD, chief medical officer at the National Alliance on Mental Illness in Arlington, Va., said in an interview. “The reason we don’t have a lot of new drug discovery is because the fundamentals of biology still need understanding. It’s a long-term goal, so it’s hard,” he added. “Everyone living with someone in their life with an illness wants better ideas now.”
The third goal is likewise challenging, Dr. Duckworth said. “That is optimistic and ... aspirational, but very important and valuable.”
Developing innovative models
Regarding the public health goal, Dr. Duckworth cited one of the objectives, to “Develop innovative service delivery models to dramatically improve the outcomes of mental health services received in diverse communities and populations.” Dr. Duckworth explained, “Trying to solve for the problem in the context of an inadequate workforce that is insufficiently diverse – it just gets to something that I’m not sure would have been a priority in the past.
“That speaks to the awakening we’re having as a society. To address some of these historic and systemic injustices and how research can play into that is really important,” Dr. Duckworth added.
Overall, he saluted the plan and its goals. Dr. Duckworth added, “We gave some feedback that we wanted more emphasis on co-occurring disorders, such as research into people with mental health and addiction [issues] and on premature mortality. I think they took some of that feedback.”
Facing ‘significant challenges’
Dr. Weine added. “It sets a path for scientific advances that are responsive to these problems.”
“The future is bright. Looking forward to the next 5 years and beyond, the new NIMH Strategic Plan for Research aims to build on these advances,” Joshua A. Gordon, MD, PhD, NIMH director, noted in his Director’s Messages blog.
“Nonetheless, we face significant challenges,” he adds. “Studies of the origins of mental illnesses suggest that a combination of causes – genetic, environmental, social, and psychological – act on the brain through a complex web of interactions, resulting in a set of heterogeneous and overlapping illnesses.”
“My hope is that the actual funding of research over the coming years reflects the comprehensive, broad, and multidisciplinary characteristics of this strategic plan,” Dr. Weine said.
The NIMH plans to its post progress for each goal on an ongoing basis on the Strategic Plan website.
Dr. Alpert, Dr. Galynker, Dr. Weine, and Dr. Duckworth had no relevant disclosures.
Today’s top news highlights: COVID-19 could worsen gambling problems, food allergies less common than thought
Here are the stories our MDedge editors across specialties think you need to know about today:
Could COVID-19 worsen gambling problems?
Take isolation, add excess available time and anxiety about illness or finances and you get the potential to increase problem gambling behaviors during the COVID-19 pandemic. A call to action, recently published in the Journal of Addiction Medicine, says it’s essential to gather data and supply guidance on this issue. “People are likely to be experiencing stress at levels they haven’t experienced previously,” said coauthor Marc N. Potenza, MD, PhD, of Yale University, New Haven, Conn. While multiple factors can contribute to addictive behaviors, “with respect to the pandemic, one concern is that so-called negative reinforcement motivations – engaging in an addictive behavior to escape from depressed or negative mood states – may be a driving motivation for a significant number of people during this time,” he said. Read more.
Food allergies in children are less frequent than expected
Food allergies appear to be less common than previously reported among 6- to 10-year-olds in Europe, according to a recent study. Prevalance ranged from a low of 1.4% to a high of 3.8%, both of which are “considerably lower” than the 16% rate based on parental reports of symptoms such as rash, itching, or diarrhea, Linus Grabenhenrich, MD, MPH, and colleagues reported in Allergy. The most commonly reported allergies were to peanuts and hazelnuts, with a prevalence of just over 5% for both. Previous research on pediatric food allergy prevalence has largely consisted of single-center studies with heterogeneous designs, the researchers noted. Read more.
The grocery store hug
William G. Wilkoff, MD, grew up in a family that didn’t embrace hugging, but as a small-town pediatrician he warmed up to the concept so much that he would frequently hug a passing acquaintance at the grocery store. That’s something he misses in the current environment and that he doesn’t expect will return. “[N]early every week I encounter one or two people with whom I have a long and sometimes emotionally charged relationship,” Dr. Wilkoff wrote in a column on MDedge. “Nurses with whom I sweated over difficult delivery room resuscitations. Parents for whom their anxiety was getting in the way of their ability to parent. Parents and caregivers of complex multiply disabled children who are now adults. Peers who have lost a spouse or a child. I’m sure you have your own list of people who send off that we-need-to-hug spark.” Read more.
Identifying structural lesions of axial spondyloarthritis
What constitutes a structural lesion of the sacroiliac joints on MRI that’s indicative of axial spondyloarthritis (axSpA) has long been a matter of conjecture, but the Assessment of SpondyloArthritis International Society (ASAS) MRI Working Group has developed new definitions that show a high degree of specificity in identifying such lesions in the disease. “Previous studies have described structural lesions in different ways, precluding meaningful comparisons between studies,” Walter P. Maksymowych, MD, said at the annual European Congress of Rheumatology, held online this year due to COVID-19. “The ASAS MRI group has generated updated consensus lesion definitions that describe each of the MRI lesions in the sacroiliac joint. These definitions have been validated by seven expert readers from the ASAS MRI group on MRI images from the ASAS classification cohort.” Read more.
Making the world’s skin crawl
Clinicians should be aware of the skin manifestations of COVID-19, especially when triaging patients. In a commentary published on MDedge, Kathleen M. Coerdt and Amor Khachemoune, MD, describe the dermatologic implications of COVID-19, including the clinical manifestations of the disease, risk reduction techniques for patients and providers, personal protective equipment-associated adverse reactions, and the financial impact on dermatologists. Read more.
For more on COVID-19, visit our Resource Center. All of our latest news is available on MDedge.com.
Here are the stories our MDedge editors across specialties think you need to know about today:
Could COVID-19 worsen gambling problems?
Take isolation, add excess available time and anxiety about illness or finances and you get the potential to increase problem gambling behaviors during the COVID-19 pandemic. A call to action, recently published in the Journal of Addiction Medicine, says it’s essential to gather data and supply guidance on this issue. “People are likely to be experiencing stress at levels they haven’t experienced previously,” said coauthor Marc N. Potenza, MD, PhD, of Yale University, New Haven, Conn. While multiple factors can contribute to addictive behaviors, “with respect to the pandemic, one concern is that so-called negative reinforcement motivations – engaging in an addictive behavior to escape from depressed or negative mood states – may be a driving motivation for a significant number of people during this time,” he said. Read more.
Food allergies in children are less frequent than expected
Food allergies appear to be less common than previously reported among 6- to 10-year-olds in Europe, according to a recent study. Prevalance ranged from a low of 1.4% to a high of 3.8%, both of which are “considerably lower” than the 16% rate based on parental reports of symptoms such as rash, itching, or diarrhea, Linus Grabenhenrich, MD, MPH, and colleagues reported in Allergy. The most commonly reported allergies were to peanuts and hazelnuts, with a prevalence of just over 5% for both. Previous research on pediatric food allergy prevalence has largely consisted of single-center studies with heterogeneous designs, the researchers noted. Read more.
The grocery store hug
William G. Wilkoff, MD, grew up in a family that didn’t embrace hugging, but as a small-town pediatrician he warmed up to the concept so much that he would frequently hug a passing acquaintance at the grocery store. That’s something he misses in the current environment and that he doesn’t expect will return. “[N]early every week I encounter one or two people with whom I have a long and sometimes emotionally charged relationship,” Dr. Wilkoff wrote in a column on MDedge. “Nurses with whom I sweated over difficult delivery room resuscitations. Parents for whom their anxiety was getting in the way of their ability to parent. Parents and caregivers of complex multiply disabled children who are now adults. Peers who have lost a spouse or a child. I’m sure you have your own list of people who send off that we-need-to-hug spark.” Read more.
Identifying structural lesions of axial spondyloarthritis
What constitutes a structural lesion of the sacroiliac joints on MRI that’s indicative of axial spondyloarthritis (axSpA) has long been a matter of conjecture, but the Assessment of SpondyloArthritis International Society (ASAS) MRI Working Group has developed new definitions that show a high degree of specificity in identifying such lesions in the disease. “Previous studies have described structural lesions in different ways, precluding meaningful comparisons between studies,” Walter P. Maksymowych, MD, said at the annual European Congress of Rheumatology, held online this year due to COVID-19. “The ASAS MRI group has generated updated consensus lesion definitions that describe each of the MRI lesions in the sacroiliac joint. These definitions have been validated by seven expert readers from the ASAS MRI group on MRI images from the ASAS classification cohort.” Read more.
Making the world’s skin crawl
Clinicians should be aware of the skin manifestations of COVID-19, especially when triaging patients. In a commentary published on MDedge, Kathleen M. Coerdt and Amor Khachemoune, MD, describe the dermatologic implications of COVID-19, including the clinical manifestations of the disease, risk reduction techniques for patients and providers, personal protective equipment-associated adverse reactions, and the financial impact on dermatologists. Read more.
For more on COVID-19, visit our Resource Center. All of our latest news is available on MDedge.com.
Here are the stories our MDedge editors across specialties think you need to know about today:
Could COVID-19 worsen gambling problems?
Take isolation, add excess available time and anxiety about illness or finances and you get the potential to increase problem gambling behaviors during the COVID-19 pandemic. A call to action, recently published in the Journal of Addiction Medicine, says it’s essential to gather data and supply guidance on this issue. “People are likely to be experiencing stress at levels they haven’t experienced previously,” said coauthor Marc N. Potenza, MD, PhD, of Yale University, New Haven, Conn. While multiple factors can contribute to addictive behaviors, “with respect to the pandemic, one concern is that so-called negative reinforcement motivations – engaging in an addictive behavior to escape from depressed or negative mood states – may be a driving motivation for a significant number of people during this time,” he said. Read more.
Food allergies in children are less frequent than expected
Food allergies appear to be less common than previously reported among 6- to 10-year-olds in Europe, according to a recent study. Prevalance ranged from a low of 1.4% to a high of 3.8%, both of which are “considerably lower” than the 16% rate based on parental reports of symptoms such as rash, itching, or diarrhea, Linus Grabenhenrich, MD, MPH, and colleagues reported in Allergy. The most commonly reported allergies were to peanuts and hazelnuts, with a prevalence of just over 5% for both. Previous research on pediatric food allergy prevalence has largely consisted of single-center studies with heterogeneous designs, the researchers noted. Read more.
The grocery store hug
William G. Wilkoff, MD, grew up in a family that didn’t embrace hugging, but as a small-town pediatrician he warmed up to the concept so much that he would frequently hug a passing acquaintance at the grocery store. That’s something he misses in the current environment and that he doesn’t expect will return. “[N]early every week I encounter one or two people with whom I have a long and sometimes emotionally charged relationship,” Dr. Wilkoff wrote in a column on MDedge. “Nurses with whom I sweated over difficult delivery room resuscitations. Parents for whom their anxiety was getting in the way of their ability to parent. Parents and caregivers of complex multiply disabled children who are now adults. Peers who have lost a spouse or a child. I’m sure you have your own list of people who send off that we-need-to-hug spark.” Read more.
Identifying structural lesions of axial spondyloarthritis
What constitutes a structural lesion of the sacroiliac joints on MRI that’s indicative of axial spondyloarthritis (axSpA) has long been a matter of conjecture, but the Assessment of SpondyloArthritis International Society (ASAS) MRI Working Group has developed new definitions that show a high degree of specificity in identifying such lesions in the disease. “Previous studies have described structural lesions in different ways, precluding meaningful comparisons between studies,” Walter P. Maksymowych, MD, said at the annual European Congress of Rheumatology, held online this year due to COVID-19. “The ASAS MRI group has generated updated consensus lesion definitions that describe each of the MRI lesions in the sacroiliac joint. These definitions have been validated by seven expert readers from the ASAS MRI group on MRI images from the ASAS classification cohort.” Read more.
Making the world’s skin crawl
Clinicians should be aware of the skin manifestations of COVID-19, especially when triaging patients. In a commentary published on MDedge, Kathleen M. Coerdt and Amor Khachemoune, MD, describe the dermatologic implications of COVID-19, including the clinical manifestations of the disease, risk reduction techniques for patients and providers, personal protective equipment-associated adverse reactions, and the financial impact on dermatologists. Read more.
For more on COVID-19, visit our Resource Center. All of our latest news is available on MDedge.com.